Growth monitoring is the cornerstone of pediatric well-child care. The WHO growth standards (0–24 months) are based on breastfed infants and represent optimal growth, while CDC growth charts (2–20 years) are used for older children in the US. Key parameters include weight, length/height, head circumference (up to 36 months), and BMI (for children ≥2 years). Microcephaly (HC <3rd percentile) warrants investigation for craniosynostosis, genetic syndromes, or congenital infections. Macrocephaly (HC >97th percentile) may indicate hydrocephalus, Sotos syndrome, or familial macrocephaly. Growth velocity is more sensitive than a single measurement — crossing ≥2 major percentile lines is always concerning. The CDC recommends routine growth assessment at every well-child visit, with BMI plotted annually starting at age 2 to screen for overweight/obesity (BMI ≥85th percentile for age and sex) and underweight (BMI <5th percentile). WHO charts are recommended internationally and for children <24 months in the US, while CDC charts are recommended for ages 2–20. Premature infants should be plotted using corrected age (gestational age plus chronological age) until 24–36 months for full catch-up.

Developmental surveillance occurs at every visit using standardized tools including the Denver II, Ages and Stages Questionnaires (ASQ), and M-CHAT-R/F for autism screening at 18 and 24 months. Gross motor milestones: lifts head prone (2mo), rolls prone to supine (4mo), sits unsupported (6mo), crawls (9mo), cruises along furniture (12mo), walks independently (15mo), runs (18mo), walks up stairs with help (24mo), hops on one foot (4yr), skips (5yr). Fine motor milestones: reaches and palmar grasp (4mo), transfers hand-to-hand (6mo), develops radial pincer grasp (9mo), scribbles spontaneously (15mo), builds tower of 3–4 cubes (18mo), copies a circle (3yr), draws a cross (4yr), copies a square (4.5yr), draws a triangle (5yr). Language milestones: coos (2mo), turns to voice (4mo), babbles consonant-vowel pairs (6mo), says mama/dada nonspecific (9mo), first specific word (12mo), has 3–5 words (15mo), two-word phrases (18mo), 50+ words and 2-word sentences (24mo), 200+ words and 3-word sentences (3yr), tells stories (4–5yr), uses past tense and plurals (5yr). Social-emotional milestones: social smile (2mo), recognizes familiar faces (4mo), stranger anxiety (6–9mo), waves bye-bye (9–12mo), plays simple interactive games (12mo), parallel play (2yr), engages in cooperative play with peers (4yr), has imaginary friends (3–4yr), develops friendships (5yr). The M-CHAT-R/F is a 20-item parent questionnaire; a positive screen requires a follow-up structured interview and, if confirmed, referral for comprehensive diagnostic evaluation and early intervention. The AAP recommends developmental screening at 9, 18, and 30 months and autism-specific screening at 18 and 24 months.

Certain missed milestones are considered absolute red flags requiring immediate evaluation and referral. Gross motor: not sitting by 9 months, not walking by 18 months, loss of previously achieved motor milestones. Fine motor: persistent hand preference before 18 months (possible hemiplegia), inability to transfer objects by 12 months. Language: not babbling by 9 months, not saying single words by 15–18 months, not using two-word phrases by 24 months (significant language delay), loss of language at any age (regression is a major red flag for autism or Landau-Kleffner syndrome). Social: no social smile by 3 months, lack of joint attention (pointing to share interest) by 18 months, no interest in other children by 3 years. The mnemonic for developmental red flags includes: loss of skills at any age (regression), head circumference crossing percentiles upward or downward, asymmetric motor function (fisting, non-use of a limb), lack of visual tracking by 3 months, persistent fisting beyond 4 months, persistent toe-walking beyond 2–3 years (may indicate cerebral palsy, autism, or idiopathic). Any child with developmental regression (loss of previously acquired skills) requires urgent neurology and metabolic evaluation including MRI brain, EEG, and metabolic/genetic testing.

Puberty onset in girls typically occurs between 8–13 years (average 10.5 years), with thelarche (breast budding, Tanner B2) as the first sign, followed by adrenarche (development of axillary and pubic hair) and menarche (average age 12.5 years, typically 2–2.5 years after thelarche). In boys, puberty begins between 9–14 years (average 11.5 years), with testicular enlargement (≥4 mL volume, Tanner G2) as the first sign, followed by penile growth, pubarche (Tanner P2), voice change (laryngeal growth), and peak height velocity. Tanner staging uses 5 stages for both breast development (B1–B5) and genital development (G1–G5) as well as pubic hair (PH1–PH5). In females, the growth spurt occurs early (peak height velocity at Tanner B2–B3, often before menarche); in males, the growth spurt occurs later (Tanner G3–G4). Precocious puberty is defined as thelarche before age 8 in girls or testicular enlargement before age 9 in boys. Evaluation includes GnRH stimulation testing (peak LH >5 IU/L confirms central puberty), bone age X-ray (advanced in central precocious puberty), and brain MRI to exclude CNS lesions (hypothalamic hamartoma, optic glioma, hydrocephalus, history of CNS radiation). Treatment of central precocious puberty: GnRH agonist (leuprolide, histrelin implant) to suppress the hypothalamic-pituitary-gonadal axis, preserve adult height potential, and manage psychosocial concerns. Delayed puberty is defined as no Tanner 2 breast development by age 13 in girls or no testicular enlargement (≥4 mL) by age 14 in boys. Etiologies include constitutional delay of growth and puberty (CDGP, most common, family history of late bloomers), functional hypogonadotropic hypogonadism (chronic illness, celiac disease, IBD, anorexia, excessive exercise, hypothyroidism), permanent hypogonadotropic hypogonadism (Kallmann syndrome: anosmia + GnRH deficiency, congenital hypopituitarism), and hypergonadotropic hypogonadism (Turner syndrome 45,X in girls, Klinefelter syndrome 47,XXY in boys, chemotherapy or radiation-induced ovarian/testicular failure).

The CDC childhood immunization schedule begins at birth with Hepatitis B vaccine (HepB, dose 1). At 1–2 months: HepB dose 2. At 2 months: rotavirus (RV, oral, 2-dose series for Rotarix or 3-dose for RotaTeq), DTaP (diphtheria, tetanus, acellular pertussis, dose 1), Hib (Haemophilus influenzae type b, dose 1), PCV13 (pneumococcal 13-valent conjugate, dose 1), and IPV (inactivated polio, dose 1). At 4 months: RV (dose 2), DTaP (#2), Hib (#2), PCV13 (#2), IPV (#2). At 6 months: HepB (#3), RV (dose 3 for RotaTeq), DTaP (#3), Hib (#3 for brand requiring 4-dose series), PCV13 (#3), IPV (#3 if using combination), and annual influenza vaccine (starting at 6 months, 2 doses first season if <9yr and no prior vaccination). At 12–15 months: MMR (measles, mumps, rubella, dose 1), varicella (VAR, dose 1), Hib (#4), PCV13 (#4), and Hepatitis A (HepA, dose 1, second dose at 18–24 months). At 15–18 months: DTaP (#4) and IPV (if not given at 6 months). At 4–6 years: DTaP (#5), IPV (#4), MMR (#2), VAR (#2). At 11–12 years: Tdap (booster), HPV (human papillomavirus, 2-dose series if started before 15th birthday, 3-dose series if started at 15 years or older), MenACWY (meningococcal conjugate, dose 1, booster at 16), and MenB (serogroup B meningococcal, 2-dose series, shared clinical decision making at 16–23 years). Annual influenza vaccine is recommended for everyone ≥6 months. COVID-19 vaccine is recommended for all ages ≥6 months, with seasonal updated formulations. For infants entering their first RSV season (<8 months), nirsevimab (long-acting monoclonal antibody) is recommended as passive immunization. For high-risk infants ≤24 months entering their second RSV season, palivizumab or nirsevimab is recommended. Catch-up schedules and accelerated immunization are available for children with delayed vaccination. Absolute contraindications to vaccination: severe allergic reaction (anaphylaxis) to a prior dose or vaccine component. Live vaccines (MMR, VAR, LAIV, rotavirus, yellow fever, RZV) are generally contraindicated in severe primary immunodeficiency, pregnancy, and certain immunosuppressive therapies.

Failure to thrive (FTT) is diagnosed when weight consistently falls below the 3rd–5th percentile, weight-for-length is <80% of ideal, or weight deceleration crosses ≥2 major percentile lines on the growth chart. Etiologies are categorized as organic (underlying medical condition: GERD, celiac disease, cystic fibrosis, congenital heart disease, chronic infection, renal tubular acidosis, endocrine disorders, inborn errors of metabolism) and non-organic/inadequate intake (psychosocial deprivation, improper formula preparation, feeding difficulties, neglect, food insecurity). A detailed history includes prenatal/perinatal history, 24-hour dietary recall, feeding behaviors (latch, sucking, coordination, refusal, gagging, vomiting), stool pattern, social history (family stressors, caregiver mental health, substance use, food access), and review of systems (vomiting, diarrhea, fever, pallor, dyspnea). Physical exam includes plotting growth parameters on appropriate charts, looking for dysmorphic features, signs of neglect, hepatosplenomegaly, heart murmur, and neurologic abnormalities. Directed laboratory evaluation: CBC (anemia, infection), CMP (electrolytes, renal function, liver enzymes, calcium, phosphate, glucose), lead level, prealbumin/albumin, inflammatory markers (ESR, CRP), celiac screen (tTG-IgA, total IgA), thyroid function (TSH, free T4), sweat chloride test (if CF suspected), urinalysis and urine culture, and stool studies (if diarrhea present). Management involves multidisciplinary intervention: nutritional rehabilitation (high-calorie formula or supplements, caloric density 22–30 kcal/oz), feeding therapy (occupational/speech therapy for oral aversions, swallowing dysfunction), social work involvement (assess food insecurity, home environment, parenting capacity, coordinate community resources), and medical management of underlying organic causes. Most children with non-organic FTT respond well to nutritional intervention and family support. Short stature is defined as height <3rd percentile for age and sex, or growth velocity <5 cm/year after age 4. Evaluation includes bone age X-ray of the left hand and wrist (delayed bone age suggests constitutional delay or GH deficiency; advanced suggests precocious puberty or obesity), IGF-1 and IGFBP-3 (screening for GH deficiency), GH stimulation testing (gold standard: two pharmacologic stimulation tests with peak GH <7–10 ng/mL confirms deficiency), celiac screening, thyroid function, CBC/BMP/ESR/CRP, karyotype (Turner syndrome in girls), and genetic testing (SHOX gene, microarray) for unexplained short stature with dysmorphic features or skeletal disproportion. SGA (small for gestational age) infants who fail to achieve catch-up growth by age 2–4 years may be candidates for recombinant human growth hormone (rhGH) therapy.

The APGAR score is a standardized assessment of the newborns transition to extrauterine life, evaluated at 1 minute and 5 minutes after birth, with repeat at 10 minutes if the 5-minute score is <7. The mnemonic APGAR covers five components each scored 0, 1, or 2: Appearance (pink all over = 2, acrocyanosis/pink body with blue extremities = 1, pale or cyanotic = 0), Pulse (heart rate >100 = 2, <100 = 1, absent = 0), Grimace (reflex irritability: vigorous cry with stimulation = 2, grimace or weak cry = 1, no response = 0), Activity (muscle tone: flexed and active motion = 2, some flexion of extremities = 1, limp/flaccid = 0), Respiration (strong cry with good respiratory effort = 2, weak cry/hypoventilation/irregular = 1, absent = 0). A score of 7–10 is reassuring and requires only routine care; 4–6 indicates moderate depression requiring stimulation, blow-by oxygen, and suctioning; 0–3 indicates severe depression requiring immediate resuscitation with PPV, intubation, chest compressions, and epinephrine as needed. The APGAR should NOT be used to guide the initiation of resuscitation, which begins immediately based on the infants breathing, heart rate, and color. The complete newborn physical exam should be performed within 24 hours of birth and includes: vital signs and growth parameters (weight, length, head circumference); general appearance and posture; head (fontanelles: anterior closes 4–26 months, posterior closes by 2–4 months; sutures; molding; caput succedaneum vs cephalohematoma); eyes (red reflex to exclude cataract, conjunctival hemorrhages), ears (shape, position, patency of external auditory canal), nose (patency to exclude choanal atresia, nasal flaring), palate (intact hard and soft palate, bifid uvula), chest (breath sounds, heart sounds, clavicles for fracture), abdomen (palpate for masses, cord vessels: normally 2 arteries and 1 vein; single umbilical artery associated with renal anomalies), genitalia (testes descended, hypospadias, chordee, ambiguous genitalia, labial adhesions), anus (patent, position), spine (palpate entire spine for defects, sacral dimple [benign if <2.5 cm from anal verge, <0.5 cm diameter, no tuft/tag/dimple], tuft of hair, hemangioma), hips (Ortolani and Barlow maneuvers for developmental dysplasia of the hip DDH, perform with each well-child visit until walking age), skin (vernix caseosa, lanugo, Mongolian spots, neonatal hemangiomas, port wine stain, nevus simplex stork bite), primitive reflexes (Moro [startle, disappears 4–6 months], rooting [disappears 3–4 months], sucking [oral reflex, persists], palmar grasp [disappears 4–6 months], Babinski [dorsiflexion of great toe normal until 12–24 months]).

Newborn screening (NBS) is a state-mandated public health program that tests for a panel of over 50 serious but treatable conditions, aiming for early detection before symptom onset prevents irreversible damage. Dried blood spot specimens are collected via heel prick 24–48 hours after birth, before hospital discharge. Core conditions tested include: phenylketonuria (PKU, elevated phenylalanine, treatment: dietary restriction of phenylalanine to prevent severe intellectual disability); congenital hypothyroidism (elevated TSH, low free T4, treatment: levothyroxine replacement started immediately, critical for neurodevelopment); G6PD deficiency (glucose-6-phosphate dehydrogenase deficiency, X-linked, hemolytic anemia triggered by oxidative stress, avoid fava beans, sulfa drugs, nitrofurantoin, dapsone); cystic fibrosis (elevated immunoreactive trypsinogen IRT, if positive then CFTR mutation analysis and sweat chloride test for confirmation); sickle cell disease (Hb electrophoresis identifies HbSS, HbSC, HbSβ-thalassemia; treatment: penicillin prophylaxis, hydroxyurea, pneumococcal vaccination); medium-chain acyl-CoA dehydrogenase deficiency (MCADD, fasting intolerance, avoid prolonged fasts >8–12 hours, carnitine supplementation); maple syrup urine disease (MSUD, branched-chain amino acid accumulation, treatment: dietary restriction of leucine, isoleucine, valine); biotinidase deficiency (biotin supplementation); congenital adrenal hyperplasia (21-hydroxylase deficiency, elevated 17-OHP, treatment: hydrocortisone and fludrocortisone for salt-wasting forms); and galactosemia (GALT deficiency, eliminate galactose from diet). Critical congenital heart disease (CCHD) screening uses pulse oximetry in the right hand (preductal) and either foot (postductal) after 24 hours of life. A positive screen is defined as SpO2 <90% in either extremity, or SpO2 90–95% in both extremities or >3% difference between hand and foot on three repeat measurements. A failed screen prompts echocardiography before discharge. Universal newborn hearing screening (EHDI program) is performed before 1 month of age using otoacoustic emissions (OAE) and/or automated auditory brainstem response (A-ABR). Infants who fail the initial screen require repeat screening; if they fail twice, comprehensive audiological evaluation by an audiologist is needed before 3 months, and early intervention services must be started before 6 months for optimal language development.

Neonatal hyperbilirubinemia is a common condition affecting approximately 60% of term and 80% of preterm newborns. Physiologic jaundice appears after 24 hours of life, peaks at day 3–5 in term infants (later in preterm), consists of unconjugated bilirubin, and resolves spontaneously within 1–2 weeks. Pathologic jaundice is characterized by onset within 24 hours, rapid rate of rise (>5 mg/dL/day or >0.5 mg/dL/hour), direct/conjugated bilirubin >2 mg/dL (or >20% of total), persistence beyond 2 weeks in term infants (or 3 weeks in preterm), or evidence of hemolysis. The Bhutani nomogram (2004 AAP guidelines) provides hour-specific total serum bilirubin (TSB) thresholds for phototherapy and exchange transfusion based on gestational age (term ≥38 weeks or late preterm 35–37 weeks) and risk factors for neurotoxicity. Phototherapy uses blue-green light (460–490 nm wavelength) which converts bilirubin to water-soluble photoisomers (lumirubin) that can be excreted without conjugation. Intensive phototherapy delivers irradiance of >30 μW/cm²/nm over the maximum body surface area. Indications for phototherapy are determined by plotting TSB on the AAP nomogram by hour of life and risk category. Exchange transfusion is indicated when TSB exceeds the exchange transfusion threshold on the nomogram (typically >25–30 mg/dL in term infants without risk factors), when there are signs of acute bilirubin encephalopathy (opisthotonos, high-pitched cry, lethargy, poor feeding, hypertonia/hypotonia), or when TSB rises rapidly despite intensive phototherapy. Neurotoxicity risk factors include hemolytic disease (ABO/Rh incompatibility, G6PD deficiency, hereditary spherocytosis, RBC enzyme defects), prematurity (<38 weeks), hypoalbuminemia (<3 g/dL), acidosis, sepsis, asphyxia, and Gilbert syndrome. Acute bilirubin encephalopathy progresses through three phases: early (lethargy, poor feeding, hypotonia), intermediate (irritability, high-pitched cry, hypertonia, arching), and advanced (opisthotonos, seizures, fever, apnea, death). Kernicterus is the chronic permanent sequelae of bilirubin neurotoxicity, causing choreoathetoid cerebral palsy, upward gaze palsy, dental enamel dysplasia, and sensorineural hearing loss.

Respiratory distress syndrome (RDS), also known as hyaline membrane disease, is primarily a disease of preterm infants (<34 weeks gestation) caused by deficiency of pulmonary surfactant — a phospholipoprotein complex produced by type II pneumocytes that reduces alveolar surface tension and prevents end-expiratory atelectasis. Surfactant production increases from 24–34 weeks gestation; infants born before 34 weeks have insufficient surfactant, leading to diffuse alveolar atelectasis, ventilation-perfusion mismatch, and progressive hypoxemia. Prenatal administration of betamethasone (two doses 24 hours apart) to mothers at risk of preterm delivery (24–33+6 weeks) accelerates fetal lung maturity and reduces the incidence and severity of RDS by up to 50%. Clinical presentation includes immediate or early postnatal tachypnea (RR >60), grunting (expiratory grunting to generate PEEP), nasal flaring, intercostal/supraclavicular/subcostal retractions, cyanosis, and diminished breath sounds. CXR classically shows low lung volumes with a diffuse ground-glass (reticulogranular) appearance and air bronchograms. Blood gas reveals hypoxemia (low PaO2) and respiratory acidosis (elevated PaCO2). Management: the cornerstone is respiratory support, starting with CPAP (continuous positive airway pressure, 5–8 cm H2O) in the delivery room for spontaneously breathing infants with respiratory distress. Surfactant replacement therapy (beractant, poractant alfa, calfactant) is administered via endotracheal tube (INSURE technique: intubation-surfactant-extubation, or less invasive LISA: less invasive surfactant administration via thin catheter during spontaneous breathing on CPAP). Criteria for surfactant administration: FiO2 >0.30–0.40 on CPAP, or intubated with worsening respiratory status. Repeated doses are sometimes needed. Ventilatory strategies include volume-targeted ventilation (preferred, reduces BPD), high-frequency oscillatory ventilation (HFOV) for severe RDS or air leak syndrome. Complications of prematurity and RDS include bronchopulmonary dysplasia (BPD, chronic lung disease of prematurity defined as requiring supplemental oxygen at 36 weeks postmenstrual age, associated with volutrauma, oxygen toxicity, inflammation, PDA, and infection), pneumothorax (air leak syndrome from high ventilation pressures), pulmonary hemorrhage, patent ductus arteriosus (PDA, associated with fluid overload), retinopathy of prematurity (ROP, screening by ophthalmology starting at 4–6 weeks postnatal age or 31–33 weeks PMA), intraventricular hemorrhage (IVH, graded I–IV by cranial ultrasound screening), necrotizing enterocolitis (NEC), and apnea of prematurity (treated with caffeine citrate).

Neonatal sepsis is categorized by timing of onset. Early-onset sepsis (EOS, ≤72 hours, usually within 24 hours) is caused by vertical transmission from the maternal genital tract during labor and delivery. The predominant pathogens are Group B Streptococcus (GBS, Streptococcus agalactiae, serotypes Ia, III, V) and Escherichia coli (accounting for 70–80% of EOS). Other pathogens include Listeria monocytogenes, Haemophilus influenzae, and other gram-negative rods. Risk factors for EOS include maternal GBS colonization (rectovaginal colonization 10–30% of pregnant women), preterm labor (<37 weeks), prolonged rupture of membranes (≥18 hours), clinical chorioamnionitis (maternal fever ≥38.0/100.4 plus two or more: uterine tenderness, fetal tachycardia, maternal tachycardia, purulent or foul amniotic fluid, maternal leukocytosis), and low birth weight. Intrapartum antibiotic prophylaxis (IAP) with IV penicillin G (5 million units load, then 2.5–3 million units every 4 hours) or ampicillin (2 g load, then 1 g every 4 hours), given at least 4 hours before delivery, reduces vertical transmission of GBS by >80%. Late-onset sepsis (LOS, onset >72 hours, typically >7 days) is nosocomial (NICU-acquired) or community-acquired. The most common pathogen is coagulase-negative Staphylococcus (CONS, especially in preterm infants with central lines), followed by S. aureus, E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter, Candida species (especially C. albicans and C. parapsilosis in very low birth weight infants), and Serratia marcescens. Clinical presentation is non-specific: temperature instability (hypothermia or hyperthermia), lethargy, irritability, poor feeding, vomiting/diarrhea, respiratory distress (grunting, tachypnea, apnea), tachycardia or bradycardia, hypotension, metabolic acidosis, glucose instability, and jaundice. Meningitis complicates 20–30% of neonatal sepsis (especially with GBS, E. coli, and Listeria) and mandates lumbar puncture. Laboratory evaluation includes CBC with differential (ANC <1000/μL or >20,000/μL, I:T ratio >0.2, platelets <150,000), CRP (elevated, often serial), procalcitonin (elevated, more specific than CRP for bacterial infection), blood culture (gold standard, obtain 1 mL minimum volume), and CSF analysis (cell count, glucose, protein, Gram stain, culture). Empiric antibiotic therapy for EOS: ampicillin (for GBS, Listeria, enterococcus) PLUS gentamicin (aminoglycoside for gram-negative coverage) OR cefotaxime (third-generation cephalosporin for gram-negative coverage, especially if meningitis suspected). Empiric therapy for LOS: vancomycin (for MRSA and CONS coverage) PLUS an aminoglycoside (gentamicin, tobramycin) or cefotaxime/ceftazidime (if Pseudomonas suspected). Antifungal therapy (fluconazole, amphotericin B) should be considered in VLBW infants with risk factors (central line, parenteral nutrition, prolonged antibiotics, fungal colonization). Duration: 7–10 days for uncomplicated bacteremia, 14–21 days for meningitis, and longer for osteomyelitis, endocarditis, or deep-seated infection.

Necrotizing enterocolitis (NEC) is a devastating gastrointestinal emergency predominantly affecting preterm infants (<32 weeks gestation, <1500 g birth weight). The pathogenesis is multifactorial: intestinal mucosal immaturity, formula feeding (breast milk is protective), altered intestinal microbiome, ischemia-reperfusion injury, and pro-inflammatory cytokine response. Modified Bell staging categorizes severity: Stage IA (suspect: feeding intolerance, abdominal distension, gastric residuals, bloody stools, normal or mildly dilated bowel loops on XR), Stage IB (same as IA but grossly bloody stools), Stage IIA (definite, mild: pneumatosis intestinalis on XR, portal venous gas), Stage IIB (definite, moderate: same as IIA plus metabolic acidosis and thrombocytopenia), Stage IIIA (advanced, intact bowel: pneumoperitoneum, peritonitis, profound hemodynamic instability), Stage IIIB (advanced, perforated bowel: pneumoperitoneum, peritonitis, shock). Management: immediate NPO status, nasogastric decompression, IV fluid resuscitation (normal saline boluses 20 mL/kg), broad-spectrum antibiotics (ampicillin + gentamicin + clindamycin/metronidazole for anaerobic coverage), serial abdominal X-rays every 6–12 hours, surgical consultation. Indications for surgery: pneumoperitoneum (intestinal perforation), worsening clinical status despite maximal medical therapy, or persistent metabolic acidosis, thrombocytopenia, and DIC. Surgical options include peritoneal drainage (for VLBW unstable infants) vs laparotomy with resection of necrotic bowel and enterostomy. Mortality: 20–30% overall, higher for Stage III (30–50%). Neurodevelopmental impairment is common in survivors. Prevention: breast milk feeding (human milk protective), standardized feeding protocols, judicious use of H2 blockers (associated with increased NEC risk in some studies), and probiotics (certain strains may reduce NEC risk in VLBW infants). Hypoxic-ischemic encephalopathy (HIE) results from perinatal asphyxia causing cerebral hypoperfusion and energy failure. Essential criteria for therapeutic hypothermia: gestational age ≥36 weeks, evidence of perinatal asphyxia (cord pH ≤7.0, base deficit ≥16, APGAR ≤5 at 10 minutes, need for resuscitation/ventilation at 10 minutes), and moderate to severe encephalopathy by Sarnat staging. Stage 1 (mild): hyperalert, jittery, exaggerated reflexes, no seizures. Stage 2 (moderate): lethargic, hypotonic, weak suck, seizures (most common stage undergoing cooling). Stage 3 (severe): stuporous/comatose, flaccid, absent reflexes, absent/ineffective respirations, fixed pupils. Therapeutic hypothermia (whole-body cooling to 33.5/34.5C for 72 hours) must be initiated within 6 hours of birth. It reduces mortality and major neurodevelopmental disability (NNT 7–8). Adjunctive therapies: aEEG/EEG for seizure monitoring, MRI brain (DWI) after rewarming to assess extent of brain injury. Neonatal hypoglycemia is common in diabetes-exposed infants (infants of diabetic mothers IDM), SGA/LGA, preterm, late preterm, and infants with birth stress (perinatal asphyxia, maternal beta-agonist therapy, polycythemia). Clinical hypoglycemia: jitteriness, hypotonia, lethargy, poor feeding, hypothermia, cyanosis, apnea, seizures. Management: early feeding (breast milk or formula) is first-line for asymptomatic borderline hypoglycemia. IV dextrose 10% at 2 mL/kg bolus followed by continuous infusion at 5–8 mg/kg/min, titrated up to 10–12 mg/kg/min if needed. Goal glucose: >50 mg/dL in the first 24 hours, >60 mg/dL thereafter. If glucose infusion rate exceeds 10–12 mg/kg/min, consider hyperinsulinism (detectable insulin/C-peptide, low ketones/BOHB, glycemic response to glucagon). Medical therapy for hyperinsulinism: diazoxide (first-line, KATP channel agonist) + chlorothiazide (to prevent fluid retention), octreotide (somatostatin analog) for diazoxide-unresponsive cases. Birth injuries include cephalohematoma (subperiosteal hemorrhage, limited by suture lines, resolves over weeks to months, associated with hyperbilirubinemia and rarely calcification or infection); caput succedaneum (subgaleal edema that crosses suture lines, resolves in days); subgaleal hemorrhage (potentially life-threatening bleed into the subaponeurotic space, presents with boggy scalp, fluctuant swelling, tachycardia, pallor, shock → immediate transfusion and neurosurgical consultation); clavicular fracture (most common birth fracture, presents with pseudoparesis of the arm, crepitus, palpable callus at 7–10 days; management: observation or arm pinned to chest for comfort, excellent prognosis); brachial plexus injury — Erb-Duchenne palsy (C5–C7: waiter tip posture — arm adducted and internally rotated, elbow extended, forearm pronated, wrist flexed; 80–90% recover spontaneously within 3–6 months; physical therapy; surgical exploration if no biceps function by 3 months), Klumpke palsy (C8–T1: total claw hand with wrist and finger flexion weakness, Horner syndrome if T1 involved; worse prognosis), and total plexus palsy (C5–T1, flail arm, poor prognosis). Facial nerve palsy: unilateral facial droop, inability to close eye, asymmetry with crying. Spontaneous recovery in >90% within weeks; protect the cornea with lubricating drops and taping.

Breast milk is the optimal source of nutrition for infants, recommended as the exclusive source of nutrition for the first 6 months of life by the AAP, WHO, and CDC, with continued breastfeeding through at least 12 months (and longer as mutually desired by mother and child). Colostrum is the first milk produced (days 1–5), rich in immunoglobulins (secretory IgA, IgG, IgM), lactoferrin, oligosaccharides (prebiotics), lysozyme, growth factors, and leukocytes, providing passive immunity and colonizing the infant gut with beneficial bacteria. Mature breast milk provides approximately 20 kcal/oz and contains 55% fat (primary energy source, essential for brain development, DHA and AA), 38% carbohydrates (lactose, which enhances calcium absorption), and 7% protein (whey-to-casein ratio of 60:40, forming soft easily digestible curds). The composition of breast milk changes dynamically over time and even within a single feed (foremilk vs hindmilk: hindmilk is higher in fat). Benefits of breastfeeding for the infant include reduced rates of acute otitis media (50% reduction), gastroenteritis (64%), lower respiratory tract infections (72%), necrotizing enterocolitis in preterm infants, SIDS (36% reduction), asthma, obesity, type 1 and type 2 diabetes, childhood leukemia, and atopic dermatitis. Benefits for the mother include reduced risk of breast cancer (4.3% reduction per 12 months), ovarian cancer, type 2 diabetes, hypertension, and myocardial infarction; improved postpartum weight loss; and enhanced mother-infant bonding. Contraindications to breastfeeding: in high-resource settings, maternal HIV infection (in low-resource settings where the risk of formula-related infection exceeds HIV transmission risk, breastfeeding may be recommended with maternal ART), active untreated tuberculosis (may resume after 2 weeks of effective therapy), HTLV-1/2, active herpes simplex lesions on the breast (may breastfeed from the unaffected breast, pump and discard from affected side), maternal use of certain medications (antimetabolites, chemotherapeutic agents, radioactive compounds, illicit drugs such as cocaine/amphetamine/PCP), and the infant with classic galactosemia (GALT deficiency). Most maternal medications are compatible with breastfeeding; the LactMed database (NIH) provides evidence-based guidance. Maternal hepatitis B or C infection is NOT a contraindication; infants receive HepB vaccine and HBIG at birth as indicated.

Proper latch is critical for successful breastfeeding and prevention of complications. Signs of a good latch: infant mouth is wide open, lower lip is flanged outward (fish lips), chin touches the breast, nose is close to but not compressed against the breast, more areola visible above the mouth than below (asymmetric latch), rhythmic sucking with a pattern of short rapid sucks followed by longer slower sucks with audible swallows (1:1:1 ratio of suck-swallow-breathe). Signs of a poor latch: painful or damaged nipples (cracked, bleeding, blistered), clicking or smacking sound, infant chewing rather than sucking, creased or flattened nipple after feeding, infant slipping off the breast, and insufficient milk transfer (fussiness after feeds, inadequate wet/soiled diapers, poor weight gain). Newborns feed 8–12 times per day (every 2–3 hours, including at night) during the first weeks. Signs of adequate intake: 6–8 wet diapers/day by day 4–5 (pale yellow urine), 3–4 stools/day (changing from black meconium to green transitional to yellow seedy by day 5), audible swallowing during feeds, contentment after feeds, appropriate weight gain (birth weight regained by 10–14 days, then 20–30 g/day in first 3 months). Engorgement occurs when the breasts become overfull with milk, blood, and lymph, causing pain, firmness, and difficulty with latch. Management: frequent feeding (at least every 2–3 hours), reverse pressure softening (gentle pressure around nipple to move edema away), cold compresses after feeds, and reverse pressure softening before feeds. Mastitis is an inflammatory condition of the breast, often infectious (S. aureus most common, also GBS, E. coli, anaerobes), presenting with unilateral breast pain, erythema, warmth, induration, fever, and flu-like symptoms. Management: continue breastfeeding or pumping on the affected side (emptying the breast is essential), NSAIDs for pain/inflammation, antibiotics for 10–14 days (dicloxacillin, cephalexin, or clindamycin if penicillin-allergic). Breast abscess (palpable fluctuant mass + fever) requires surgical drainage (aspiration under US guidance vs incision and drainage) in addition to antibiotics. Low milk supply is a common concern. True low supply must be distinguished from perceived insufficient milk. Causes of true low supply: inadequate breast stimulation (infrequent feeding, poor latch, scheduled feeds), maternal factors (hypoplasia, prior breast surgery, PCOS, hypothyroidism, retained placenta, Sheehan syndrome), medications (pseudoephedrine, estrogen-containing OCPs, dopamine agonists), and infant factors (cleft palate, tongue-tie, neurologic impairment). Management: improve latch and frequency (8–12 feeds per day including nights), ensure proper milk removal, skin-to-skin contact, and consider galactagogues (domperidone 10–20 mg TID, not FDA-approved but commonly used, risk of QTc prolongation; metoclopramide is less effective with more side effects).

When breastfeeding is not possible, insufficient, or contraindicated, iron-fortified infant formula is the only safe alternative during the first 12 months. Standard cow milk-based formulas (whey-to-casein ratio 60:40, similar to breast milk) are appropriate for most term infants. Types include: milk-based (Similac Advance, Enfamil NeuroPro, Gerber Good Start), soy-based (indicated for classic galactosemia, vegan families, or congenital lactase deficiency; NOT recommended for cow milk protein intolerance as 30–60% of affected infants also react to soy), extensively hydrolyzed protein (EHCF, semi-elemental for cow milk protein intolerance, e.g., Nutramigen, Alimentum, Pregestimil; 90% of CMPI infants tolerate these), amino acid-based (elemental for severe CMPI, eosinophilic esophagitis, multiple food protein intolerance, e.g., Neocate, EleCare, PurAmino), and specialized formulas (preterm formulas, metabolic formulas for PKU/MSUD). Preparation: standard dilution is 1 unpacked level scoop of powder per 2 ounces of water (provides ~20 kcal/oz). Formula should never be over-concentrated (risks hypernatremia, dehydration) or under-concentrated (risks water intoxication, hyponatremia, poor weight gain). Water used for formula: for term infants >2 months in areas with safe tap water, tap water is acceptable. For infants <2 months, preterm, or immunocompromised infants, use boiled and cooled water (to ≥160F, then cooled to body temperature) due to risk of Cronobacter sakazakii (formerly Enterobacter sakazakii) infection, which causes severe meningitis and NEC. Ready-to-feed formula is sterile and preferred for high-risk infants. Prepared formula must be refrigerated and used within 24 hours; formula left at room temperature for >1 hour or leftover from a feeding should be discarded. Iron fortification: all term infants should receive iron-fortified formula (10–12 mg/L iron) if not breastfed. Low-iron formulas should NOT be used. Cow milk should NOT be given as the primary milk before 12 months of age due to inadequate iron content (poorly absorbed), high renal solute load, protein excess, and risk of occult GI bleeding that contributes to iron deficiency anemia. After 12 months, whole milk (3.25% milk fat) is recommended until age 2 to provide adequate fat for brain development. At age 2, transition to reduced-fat (2% or 1%) or skim milk if BMI is adequate and there is no concern about growth. Goat milk is not recommended for infants unless specifically formulated as infant formula with appropriate fortification (unmodified goat milk is deficient in folate, vitamin B12, vitamin D, and iron). Plant-based milks (almond, oat, soy, rice) are inappropriate for infants.

Complementary feeding (the introduction of solid foods) should begin around 6 months of age (not before 4 months, not after 6–8 months), when the infant demonstrates developmental readiness: sits with minimal support, demonstrates good head and neck control, opens mouth when food is offered, actively closes lips around a spoon, can transfer food to the back of the mouth and swallow (loss of extrusion reflex), and shows interest in foods. Continue breastfeeding or formula on demand (approximately 24–32 oz/day at 6–12 months) while introducing solids. Iron-rich foods should be the first complementary foods introduced because infant iron stores become depleted by 4–6 months of age. Good first foods include iron-fortified single-grain infant cereal (mixed with breast milk or formula), pureed meat (chicken, beef, turkey), pureed poultry, pureed beans/lentils, and pureed tofu. Introduce one single-ingredient food at a time (with no added salt, sugar, or seasoning) and observe for allergic reactions. There is no evidence that delaying the introduction of common allergens beyond 6–12 months prevents food allergy; in fact, early introduction reduces allergy risk. The LEAP study demonstrated that early introduction of peanut between 4–11 months in high-risk infants (severe eczema, egg allergy) reduced peanut allergy by 86%. The EAT study found that introduction of six allergenic foods (peanut, egg, cow milk, sesame, whitefish, wheat) from 3 months in exclusively breastfed infants reduced food allergy, but adherence was low. Current AAP/NIAID guidelines: for high-risk infants (severe eczema, egg allergy), introduction of peanut-containing foods should be evaluated at 4–6 months after assessment (sIgE/skin prick test or in-office feeding). For moderate-risk (mild eczema) and low-risk infants, peanut can be introduced at home around 6 months. For other allergens (egg, milk, soy, tree nuts, fish, shellfish, wheat, sesame), there is no specific restriction; introduce at around 6 months of age. Texture progression: pureed (6 months) → mashed and lumpy (7–9 months) to encourage chewing and oral motor development → soft finger foods (9–12 months: soft cooked vegetables, soft fruits, small soft pieces of meat, toast strips) → family foods with modifications (12+ months). Honey should not be given before 12 months due to the risk of infant botulism (Clostridium botulinum spores germinate in the immature gut and produce botulinum toxin). Choking hazards: hot dogs, whole grapes, raw carrots, nuts, seeds, popcorn, hard candy, marshmallows, spoonfuls of peanut butter. Juice: not recommended before 12 months (empty calories, risk of dental caries, diarrhea, and malnutrition). After 12 months, limit 100% fruit juice to 4 oz/day (ages 1–3), 4–6 oz/day (ages 4–6), and 8 oz/day (ages 7–18). Water intake: 4–8 oz/day at 6–12 months, 8–32 oz/day (1–4 cups) for toddlers.

Vitamin D: all breastfed infants and infants consuming <1 L/day (<32 oz/day) of vitamin D-fortified formula require 400 IU/day of oral vitamin D supplementation starting at birth (or shortly after) and continuing through at least 12 months of age. After 12 months, 600 IU/day of vitamin D is recommended if the child has inadequate sun exposure or dietary intake. The AAP recommends 400 IU/day for all children regardless of feeding type, as vitamin D deficiency remains prevalent. Iron supplementation: exclusively breastfed term infants require 1 mg/kg/day of oral elemental iron starting at 4 months of age, continued until iron-rich complementary foods are established at ~6 months. Preterm infants (<37 weeks) require 2–3 mg/kg/day of oral elemental iron starting at 2 weeks of age through 12 months. Infants receiving formula receive adequate iron (12 mg/L) and do not need supplementation. Toddlers at risk for iron deficiency (excessive cow milk, picky eaters, vegetarian diet) may need screening and supplementation. Fluoride supplementation is recommended if the local water supply contains less than 0.3 ppm fluoride: ages 0–3 years: 0.25 mg/day; ages 3–6 years: 0.5 mg/day; ages 6–16 years: 1.0 mg/day. Use of fluoridated toothpaste (a grain-of-rice-sized smear for children <3 years, a pea-sized amount for ages 3–6 years) is recommended. Vitamin B12: breastfed infants of vegan or B12-deficient mothers may need B12 supplementation. Vitamin K: all newborns receive 1 mg of vitamin K IM at birth to prevent Vitamin K Deficiency Bleeding (VKDB, previously known as hemorrhagic disease of the newborn), which can cause catastrophic intracranial hemorrhage. Vitamin E: routine supplementation is not needed in term infants. For preterm infants <1500 g, multivitamin supplementation including vitamins A, D, E, and K is often prescribed until reaching 2 kg or full enteral feeds.

Childhood obesity (BMI ≥95th percentile for age and sex) affects approximately 20% of US children and adolescents, with disparities among Black, Hispanic, and lower-income populations. The 5-2-1-0 evidence-based framework provides simple behavioral targets: 5 or more servings of fruits and vegetables daily, 2 hours or less of recreational screen time per day (avoid screen time before 18–24 months except video calls), 1 hour or more of moderate-to-vigorous physical activity daily, and 0 sugary drinks (promote water and plain milk). Motivational interviewing is an effective counseling technique that uses open-ended questions, reflective listening, and collaborative goal-setting. Assess the patients stage of change (precontemplation, contemplation, preparation, action, maintenance) before providing recommendations. For children with obesity, family-based multicomponent lifestyle interventions (dietary modification, increased physical activity, decreased sedentary behavior, behavioral counseling) remain the cornerstone. Pharmacotherapy is indicated for adolescents ≥12 years with BMI ≥95th percentile as adjunct to lifestyle modifications: metformin, orlistat, and GLP-1 receptor agonists (liraglutide, semaglutide) are FDA-approved. Bariatric surgery is an option for adolescents with BMI ≥35 with significant comorbidity (type 2 diabetes, severe OSA, NAFLD, pseudotumor cerebri, Blount disease, SCFE, hypertension, dyslipidemia) or BMI ≥40, performed in experienced multidisciplinary centers. Comorbidities: type 2 diabetes (increasing in adolescents), NAFLD, hypertension, dyslipidemia, OSA (adenotonsillar hypertrophy from adipose deposition), pseudotumor cerebri (idiopathic intracranial hypertension), slipped capital femoral epiphysis (SCFE, hip/knee pain, limited internal rotation, X-ray diagnosis, surgical pinning), Blount disease (tibia vara, orthopedic management), polycystic ovary syndrome, and psychosocial consequences (depression, anxiety, bullying, low self-esteem, disordered eating). Nutritional rickets is caused by vitamin D deficiency and/or inadequate calcium intake, leading to impaired mineralization of growing bone. At-risk populations: exclusively breastfed infants without vitamin D supplementation, dark-skinned infants, those with limited sun exposure, and malabsorptive conditions (CF, celiac disease, IBD, cholestatic liver disease). Clinical features: craniotabes (soft skull bones in young infants), frontal bossing, rachitic rosary (beading at costochondral junctions), Harrison groove (horizontal indentation at diaphragm insertion), widened wrists and ankles, genu varum (bowlegs, once weight-bearing starts) or genu valgum, short stature, hypocalcemic tetany, and seizures in severe acute hypocalcemia. Labs: low 25-hydroxyvitamin D (<12–20 ng/mL), low-normal or low serum calcium, low serum phosphate, markedly elevated alkaline phosphatase, elevated PTH (secondary hyperparathyroidism). Radiographic changes at the growth plates (metaphyses): cupping, fraying, widening of the physis, and decreased bone density. Treatment: vitamin D 2000–6000 IU/day for 8–12 weeks (some use single high-dose 150,000 IUs stoss therapy), then transition to maintenance 400–1000 IU/day. Ensure adequate calcium intake (500–1000 mg/day from dietary sources or supplements). Monitor ALP, Ca, PO4, and radiographic healing. Iron deficiency anemia (IDA) is the most common nutritional deficiency, peaking at 12–24 months. Prevention: iron-rich complementary foods, limit cow milk to ≤24 oz/day, and screening hemoglobin at 12 months (universal screening recommended by AAP). Labs: microcytic (low MCV), hypochromic anemia, elevated RDW, low ferritin (<12–15 ng/mL), low serum iron, elevated TIBC, low transferrin saturation (<16%). Treatment: oral ferrous sulfate 3–6 mg/kg/day elemental iron in two divided doses, given between meals with vitamin C (ascorbic acid) to enhance absorption, avoiding milk, tea, and calcium simultaneously. Response: reticulocytosis in 3–7 days, Hb rise of 1 g/dL in 2–4 weeks. Continue supplementation for 2–3 months after Hb normalizes to replenish iron stores. IV iron is reserved for non-adherence, intolerance, malabsorption (IBD, celiac), or severe anemia with need for rapid correction. Eating disorders in adolescents: anorexia nervosa (restrictive eating, intense fear of weight gain, body image disturbance), bulimia nervosa (binge-purge cycle), and ARFID (restrictive eating without body image disturbance, often sensory sensitivities, fear of choking/vomiting, or lack of interest in food). Medical complications: bradycardia, hypotension, orthostatic instability, prolonged QTc interval, electrolyte disturbances (hypokalemia, hypophosphatemia, hypomagnesemia), amenorrhea (in females), delayed puberty/growth arrest, decreased bone mineral density (osteopenia/osteoporosis), refeeding syndrome (severe hypophosphatemia, hypokalemia, hypomagnesemia, fluid shifts, cardiac arrhythmias, seizures, death). Management: multidisciplinary team (medical, nutrition, mental health), medical stabilization, weight restoration (inpatient if <75% ideal body weight or severe medical instability, outpatient with close monitoring otherwise), monitored refeeding with close electrolyte monitoring (starting calories at 30–50% of goal to prevent refeeding syndrome, advancing slowly), family-based treatment (FBT, Maudsley approach) for adolescents with anorexia, CBT for bulimia, and SSRIs for comorbid anxiety/depression.

Acute otitis media (AOM) is most common at 6–24 months, and diagnosis requires three elements: acute onset of symptoms (otalgia, fever, irritability, tugging at ears), middle ear effusion (bulging TM, decreased or absent mobility on pneumatic otoscopy, opaque or yellow TM with loss of landmarks), and signs of middle ear inflammation (erythema of TM, otorrhea). Pathogens: Streptococcus pneumoniae (most common post-PCV but serotype replacement is happening), Haemophilus influenzae (nontypeable, now more common post-PCV), Moraxella catarrhalis, Group A Streptococcus, and viruses (RSV, influenza, rhinovirus). First-line antibiotic: amoxicillin 80–90 mg/kg/day divided BID for 5–10 days (5 days if ≥2 years with mild-moderate disease, 10 days if <2 years or severe). For treatment failure after 48–72 hours or recent antibiotic use: amoxicillin-clavulanate (90 mg/kg/day of amoxicillin component). For severe penicillin allergy (IgE-mediated): clindamycin or levofloxacin (off-label). Tympanostomy tubes are indicated for recurrent AOM (≥3 episodes in 6 months or ≥4 in 12 months) or persistent middle ear effusion (>3 months with hearing loss ≥20 dB). Prevention: PCV13, annual influenza vaccine, and avoidance of smoke exposure and pacifier use after 6 months. Group A Streptococcal (GAS) pharyngitis occurs in children 5–15 years with sore throat, fever, tonsillar exudates, tender anterior cervical lymphadenopathy, and absence of cough. Centor criteria plus age adjustment (McIsaac criteria) guide the decision to test. RADT is highly specific (>95%) but moderately sensitive (70–90%); negative RADT in children ≥3 years should be confirmed by throat culture. Treatment: amoxicillin 50 mg/kg once daily (max 1000 mg) or penicillin V 250 mg BID/TID for 10 days. For non-anaphylactic penicillin allergy: first-generation cephalosporin (cephalexin). For IgE-mediated allergy: clindamycin or azithromycin. Non-suppurative complications: acute rheumatic fever (ARF, develops 2–4 weeks after GAS pharyngitis, although only rheumatogenic strains, typically M types 1, 3, 5, 6, 18, 19, 24) and post-streptococcal glomerulonephritis (PSGN, 1–3 weeks after GAS pharyngitis or impetigo). Suppurative complications: peritonsillar abscess (trismus, hot potato voice, medial deviation of the soft palate, CT confirmation, drainage + abx), retropharyngeal abscess (young children, stiffness, drooling, muffled stridor, XR/CT, I&D + abx), and cervical lymphadenitis. Bronchiolitis is a clinical diagnosis in infants <12–24 months (peak 2–6 months) with coryza, cough, tachypnea, wheezing, crackles, and accessory muscle use during the winter/spring RSV season. RSV is the most common etiology (50–80%), followed by rhinovirus, hMPV, influenza, adenovirus, and bocavirus. Management is supportive: nasal suctioning (deep suctioning of the nasopharynx), upright positioning, supplemental oxygen to maintain SpO2 ≥90%, high-flow nasal cannula (HFNC, 1–2 L/kg/min) for moderate respiratory distress and hypoxemia, and IV/NG fluids if the infant cannot maintain oral hydration. Medications do NOT reduce mortality or hospital stay: bronchodilators (albuterol) are not recommended (no benefit, side effects); systemic corticosteroids are not recommended (no benefit in viral bronchiolitis); chest physiotherapy is not beneficial; nebulized epinephrine is not recommended except in the ED as a single trial in severe cases. Croup (laryngotracheobronchitis) typically affects children 6 months to 3 years, with a barking seal-like cough, hoarse voice, inspiratory stridor, and often worse at night. Parainfluenza virus (types 1–3) is the most common cause. The Westley Croup Score assesses severity: mild (barking cough, no stridor at rest, no retractions), moderate (stridor at rest, retractions, but no significant distress), severe (stridor with severe retractions, agitation, lethargy, hypoxemia, pallor/cyanosis). Treatment: a single dose of dexamethasone 0.15–0.6 mg/kg PO/IM/IV (max 10 mg) for all severities (symptomatic improvement within 6 hours). Racemic epinephrine (0.25–0.5 mL of 2.25% solution nebulized, or L-epinephrine 1:1000 0.5 mL/kg, max 5 mL) for moderate-severe croup with stridor at rest; observe for 2–4 hours after to monitor for rebound. Heliox (70:30 helium-oxygen mixture) may reduce the work of breathing. Intubation is needed in <1% of cases (impending respiratory failure: severe retractions, exhaustion, cyanosis, altered mental status, or failure to respond to therapy). Bacterial tracheitis is a superinfection (S. aureus, GAS, M. catarrhalis, H. influenzae) causing purulent tracheal secretions, high fever, toxic appearance, and failure to respond to croup therapy; requires direct laryngoscopy for diagnosis, IV antibiotics, and often intubation.

Measles (rubeola) is caused by measles virus (paramyxovirus), one of the most contagious infectious diseases (R0 12–18). Prodrome: 3–4 days of cough, coryza (runny nose), conjunctivitis (the 3 Cs), and high fever, with pathognomonic Koplik spots (bluish-white spots on the buccal mucosa opposite the molars) appearing 1–2 days before the rash. The erythematous maculopapular rash starts at the hairline and behind the ears, spreads downward to the face, trunk, and extremities over 3–4 days, and fades in the same order with fine desquamation. Complications: pneumonia (most common cause of measles death), encephalitis (1 in 1000, high morbidity), secondary bacterial infection (otitis media, pneumonia), and subacute sclerosing panencephalitis (SSPE, 1 in 10,000–100,000, a rare fatal neurodegenerative disease developing 7–10 years after infection characterized by myoclonus, progressive neurologic deterioration, and death). Treatment: supportive care; vitamin A (200,000 IU for 2 days, reduces mortality and complications in endemic areas). Prevention: MMR vaccine (2 doses: 1st at 12–15 months, 2nd at 4–6 years; 93% efficacy after 1 dose, 97% after 2). Rubella (German measles): mild illness with posterior auricular and suboccipital lymphadenopathy, arthralgias/arthritis (especially in women), and a pinkish maculopapular rash starting on the face. The greatest concern is congenital rubella syndrome (CRS) in infants born to infected mothers during the first trimester: deafness (sensorineural hearing loss), cardiac defects (PDA, pulmonary artery stenosis), cataracts, microcephaly, IUGR, and intellectual disability. Prevention: MMR vaccine. Roseola infantum (exanthem subitum, sixth disease): caused by HHV-6 (or HHV-7), most common in infants 6–24 months. Classic presentation: abrupt high fever (39–40.5C) for 3–5 days in an otherwise well-appearing child (the fever is high but the child does not look toxic), followed by a rapid defervescence (crisis) coinciding with the appearance of a rose-pink maculopapular rash on the trunk and neck (spreading to face and extremities). The rash is non-pruritic, blanches with pressure, and lasts 1–2 days. Febrile seizures occur in 5–15% due to rapid temperature rise. Treatment: supportive (antipyretics for comfort). Erythema infectiosum (Fifth disease, slapped cheek disease): caused by Parvovirus B19. The classic slapped cheek appearance (confluent erythema on the cheeks) is followed 1–4 days later by a lacy, reticular, symmetric maculopapular rash on the trunk and extremities that may wax and wane for weeks with heat, sunlight, and exercise. Joint pain (arthropathy) is common in older children and adults. Aplastic crisis (transient arrest of erythropoiesis): seen in patients with underlying hemolytic anemias (sickle cell disease, hereditary spherocytosis, thalassemia, pyruvate kinase deficiency) → rapid drop in hemoglobin, reticulocytopenia (<1%), and requires transfusion support. The aplastic crisis is self-limited, with reticulocytosis in 7–10 days. Infection during pregnancy: risk of hydrops fetalis (non-immune hydrops) due to severe fetal anemia and high-output heart failure, especially in the first 20 weeks. Scarlet fever (scarlatina): caused by GAS exotoxin (erythrogenic toxin), producing diffuse erythematous blanching sandpaper-like rash (feels rough, like goosebumps), circumoral pallor, strawberry tongue (initially white strawberry, then red strawberry after desquamation), Pastia lines (petechial linear accentuation in skin folds), and desquamation of the palms and soles during convalescence. Treatment: penicillin or amoxicillin for 10 days (to prevent ARF). Hand-foot-and-mouth disease (HFMD): most commonly caused by Coxsackievirus A16 (mild) and Enterovirus A71 (potentially severe). Presents with fever, vesicular lesions on the palms and soles, and painful oral ulcers/vesicles on the buccal mucosa, tongue, palate, and oropharynx. Enterovirus A71 can cause severe neurologic disease (brainstem encephalitis, myoclonus, autonomic dysregulation, pulmonary edema, cardiopulmonary collapse) and requires close monitoring. Treatment: supportive, analgesia for painful oral lesions.

Fever without source (FWS) is defined as a temperature ≥38.0C in an infant or young child (<36 months) who appears well and has no localizing signs of infection after thorough history and physical examination. The risk of serious bacterial infection (SBI: UTI, bacteremia, meningitis, bacterial enteritis) is highest in neonates and infants <90 days. The AAP and NICE guidelines recommend risk-stratified management. For well-appearing infants 8–21 days: full sepsis evaluation (CBC with differential, blood culture, catheterized urinalysis and culture, CSF analysis and culture, CXR if respiratory symptoms), empiric antibiotics (ampicillin + gentamicin or ampicillin + cefotaxime). For infants 22–28 days: consider the Rochester criteria for low risk (well-appearing, full-term, no prior/history of antibiotic use, WBC 5–15K, band count <1500, normal UA, reliable follow-up); if all met, some centers manage without LP or antibiotics, but approach varies. For well-appearing infants 29–60 days: the AAP 2021 guideline (based on the STEP trial and PECARN rule) suggests that if the infant is well-appearing, has no fever source, has reassuring labs (WBC normal, absolute band count <1500, procalcitonin <0.5 ng/mL, and negative UA), the risk of SBI is <1–2% and they can be managed as outpatients without antibiotics. For infants 61–90 days, similar approach. Procalcitonin is the most sensitive single biomarker for invasive bacterial infection (threshold <0.5 ng/mL is low risk). Urinary tract infection is the most common SBI in febrile infants <24 months without a source, affecting 7–8% of febrile girls <12 months and 2–3% of circumcised boys. E. coli accounts for 80–85% of UTIs, followed by Klebsiella, Proteus, Enterococcus, and Enterobacter. Diagnosis requires catheterized or suprapubic aspirate specimen: ≥50,000 CFU/mL of a single uropathogen. Empiric antibiotic therapy: IV ceftriaxone (if ill-appearing, dehydrated, unable to tolerate PO, or <2 months), or oral cefdinir, cefixime, or amoxicillin-clavulanate (if well-appearing, ≥2 months, dehydrated). Duration: 7–14 days (7 days for uncomplicated febrile UTI, 14 days for complicated or with bacteremia). Renal and bladder ultrasound is indicated after first febrile UTI in all children <2 years. Voiding cystourethrogram (VCUG) is indicated if RBUS is abnormal (hydrocephalus, hydronephrosis, renal scarring, duplication), or for recurrent febrile UTIs.

Kawasaki disease (KD) is an acute systemic vasculitis of medium-sized arteries, primarily affecting children 6 months to 5 years (peak 12–24 months), and is the leading cause of acquired heart disease in children in developed countries. The etiology remains unknown but is thought to be triggered by an infectious agent in genetically susceptible individuals. Classic (complete) KD diagnosis requires fever ≥5 days (or fewer if criteria are met) plus 4 of 5 principal clinical features: (1) bilateral bulbar conjunctival injection (non-exudative, spares the limbus, painless); (2) oral mucous membrane changes (erythema, cracked/fissured lips, strawberry tongue, diffuse oropharyngeal hyperemia); (3) polymorphous erythematous rash (truncal, often non-specific, can be maculopapular, morbilliform, target-like, or scarlatiniform but NOT vesicular); (4) extremity changes (acute phase: erythema and/or edema of hands and feet, often painful and limiting use; subacute phase: periungual desquamation of fingers and toes 2–3 weeks after fever onset); (5) cervical lymphadenopathy (≥1.5 cm in diameter, usually unilateral, anterior cervical, non-suppurative, the least common feature occurring in ~50%). Incomplete (atypical) KD should be considered in children with unexplained fever ≥5 days and 2–3 of the principal features, especially infants <6 months and older children. The diagnosis is supported by laboratory markers (CRP ≥3 mg/dL, ESR ≥40 mm/h, leukocytosis with left shift, anemia, hypoalbuminemia, thrombocytosis after 7 days, elevated ALT, sterile pyuria, and CSF pleocytosis) and echocardiographic findings (coronary artery dilation or ectasia, perivascular brightness, decreased LV contractility, mitral or aortic regurgitation, and pericardial effusion). Echocardiography should be performed at baseline (diagnosis), 2 weeks, and 6–8 weeks after diagnosis. Coronary artery abnormalities (ectasia, dilation, or aneurysm) develop in 20–25% of untreated cases but decrease to 3–5% with IVIG treatment within 10 days. Aneurysm classification (by Z-score): small (<5 mm or Z-score 2.5–5), medium (5–8 mm or Z-score 5–10), giant (>8 mm or Z-score >10). Treatment: IVIG 2 g/kg as a single infusion (over 8–12 hours) plus high-dose aspirin (80–100 mg/kg/day divided every 6 hours) in the acute phase for anti-inflammatory effect. After defervescence (24–48 hours after IVIG completion), transition to low-dose aspirin (3–5 mg/kg/day) for antiplatelet effect, continued until 6–8 week echo confirms normal coronary arteries. Patients with persistent coronary abnormalities continue aspirin lifelong. IVIG resistance (persistent or recrudescent fever ≥36 hours after IVIG completion) occurs in 10–20%; risk factors include age <6 months, male sex, low albumin, low sodium, elevated CRP, low IgG, and high neutrophil-to-lymphocyte ratio. Treatment of IVIG-resistant KD: second dose of IVIG 2 g/kg with or without high-dose methylprednisolone (30 mg/kg/day ×3 days) or infliximab (5 mg/kg, anti-TNF). Adjunctive therapies: calcineurin inhibitors (cyclosporine), anakinra (IL-1RA). KD shock syndrome (KDSS): patients with hypotension and shock require ICU management, IVIG, inotropic support, and may require infliximab. Long-term management: coronary aneurysm size determines follow-up: small → aspirin, echo q1–2y; medium → aspirin, echo annually, stress test q2–3y; giant (≥8mm) → aspirin + warfarin/enoxaparin (due to high thrombosis risk), serial echo, cardiac catheterization, stress testing, and cardiology follow-up indefinitely. Risk of myocardial infarction in giant aneurysms is highest in the first 2 years.

Vaccine-preventable diseases remain a cause of morbidity in undervaccinated populations. Pertussis (whooping cough) caused by Bordetella pertussis presents with 1–2 weeks of catarrhal stage (coryza, cough) followed by paroxysmal stage (bursts of rapid cough followed by the characteristic whoop and post-tussive emesis). Infants <6 months may present with apnea and cyanosis rather than typical paroxysms. Diagnosis: nasopharyngeal PCR is most sensitive for early disease. Treatment: azithromycin (10 mg/kg/day ×5 days) for the patient and all household contacts regardless of vaccine status (post-exposure prophylaxis). Prevention: DTaP (acellular) at 2, 4, 6, 18 months and 4–6 years; Tdap booster at 11–12 years and during pregnancy (27–36 weeks) to protect neonates (Tdap cocooning strategy). Varicella (chickenpox): generalized pruritic vesicular rash (dew drops on a rose petal) that progresses from macules to vesicles to pustules to crusts, with crops in varying stages, fever, and malaise. Complications: secondary bacterial infection (GAS, S. aureus, with risk of necrotizing fasciitis and toxic shock syndrome), pneumonia (especially in adolescents and immunocompromised), encephalitis (cerebellar ataxia), and Reye syndrome (with aspirin use). Treatment: acyclovir if started within 24–48 hours of rash onset, or for high-risk patients (adolescents, pregnancy, immunocompromised, chronic skin/lung disease). Prevention: varicella vaccine (2 doses). Mumps: parotid swelling (unilateral or bilateral), orchitis (in postpubertal males, risk of infertility), oophoritis, aseptic meningitis, and sensorineural hearing loss (can be permanent). Prevention: MMR vaccine. Multisystem inflammatory syndrome in children (MIS-C) is a post-infectious hyperinflammatory syndrome associated with SARS-CoV-2, typically occurring 2–6 weeks after infection. Diagnostic criteria (CDC): fever ≥38.0C for ≥24 hours, hospitalization, multisystem organ involvement (≥2 organ systems: cardiovascular, GI, mucocutaneous, respiratory, neurologic, renal, hematologic), elevated inflammatory markers (CRP, ESR, ferritin, D-dimer, procalcitonin, IL-6, fibrinogen), and evidence of recent SARS-CoV-2 infection (positive PCR or serology, or known exposure). Cardiovascular involvement is the hallmark: myocardial dysfunction (low LVEF), coronary artery dilation/aneurysm (similar to KD), shock requiring vasopressors, and arrhythmias. Treatment: IVIG 2 g/kg (first-line, many respond), high-dose methylprednisolone (2 mg/kg/day or pulse 30 mg/kg/day) for moderate-severe disease, and supportive care (inotropic support, respiratory support, therapeutic anticoagulation with enoxaparin if severely elevated D-dimer or coronary aneurysm). Anakinra (IL-1RA) and infliximab (anti-TNF) are used for refractory cases. Patients typically respond well, though long-term follow-up for cardiac function is needed. Emerging infections: Invasive group A streptococcal (GAS) infections have surged post-COVID-19, including necrotizing fasciitis (pain out of proportion, erythema/edema/crepitus, bullae, rapid spread, surgical emergency), streptococcal toxic shock syndrome (hypotension, multi-organ failure), and pneumonia with empyema. Early recognition, aggressive IV antibiotics (clindamycin + penicillin, which are synergistic), are critical. Influenza: annual vaccination is recommended for all ≥6 months; antivirals (oseltamivir) are most effective when started within 48 hours of symptom onset and are recommended for high-risk groups (children <2 years, any with chronic medical conditions, immunocompromised, pregnant) regardless of symptom duration.

Congenital heart disease (CHD) affects approximately 1% of live births (8–10 per 1000), making it the most common birth defect. CHD accounts for 30% of infant deaths due to birth defects. The classification is based on pathophysiology: acyanotic (left-to-right shunt: VSD, ASD, PDA, AVSD) and cyanotic (right-to-left shunt or mixing: TOF, TGA, truncus arteriosus, tricuspid atresia, TAPVR, HLHS) or obstructive (coarctation, aortic stenosis, pulmonary stenosis). Critical CHD refers to defects requiring intervention in the first days or weeks of life, often ductal-dependent. Newborns are screened for critical left-sided obstructive lesions using preductal and postductal pulse oximetry between 24–48 hours of life. An abnormal screen (SpO2 <90% in either extremity, or 90–95% with >3% difference between hand and foot) prompts echocardiogram. Fetal echocardiography can detect most major CHD prenatally. Genetic associations: 22q11.2 deletion (conotruncal anomalies: TOF, truncus arteriosus, interrupted aortic arch, right aortic arch), trisomy 21 (AVSD, VSD, ASD), Turner syndrome (coarctation, bicuspid aortic valve), Noonan syndrome (pulmonary valve stenosis, hypertrophic cardiomyopathy), Williams syndrome (supravalvular aortic stenosis), Alagille syndrome (peripheral pulmonary stenosis), and CHARGE syndrome. Chest XR: evaluates cardiac silhouette (boot-shaped heart in TOF, egg-on-side in TGA), pulmonary vascularity (increased in left-to-right shunts, decreased in cyanotic CHD with pulmonary stenosis), and situs. ECG: assesses axis (left axis deviation in AVSD, right axis deviation in TOF), ventricular hypertrophy (RVH in tetralogy, LVH in VSD), and conduction delays. Echocardiography is the primary diagnostic modality, providing anatomy, hemodynamics, and ventricular function.

Ventricular septal defect (VSD) is the most common CHD, accounting for 30–40%. Small VSDs (<5 mm, muscular) often close spontaneously by 2 years, and may present with a loud holosystolic murmur at the left lower sternal border (LLSB) that can sound softer as the defect closes. Moderate to large VSDs present with tachypnea, poor feeding, diaphoresis with feeding, FTT, and signs of heart failure at 4–8 weeks as pulmonary vascular resistance drops and left-to-right shunt increases. Medical management: diuretics (furosemide), afterload reduction (ACE inhibitors), and caloric supplementation (high-calorie formula, nasogastric feeds). Surgical repair (patch closure via median sternotomy or minimally invasive) is indicated for large VSDs with heart failure unresponsive to medical therapy, pulmonary hypertension (Eisenmenger physiology), or failure to thrive. Eisenmenger syndrome (irreversible pulmonary hypertension with right-to-left shunt) is a late complication of unrepaired large left-to-right shunts, causing cyanosis, clubbing, polycythemia, and risk of paradoxical embolism. Atrial septal defect (ASD) is more common in females, with a fixed, widely split S2, and a systolic flow murmur at the left upper sternal border (LUSB). Most ASDs are asymptomatic in childhood; symptoms (exertional dyspnea, fatigue, atrial arrhythmias, rarely HF) develop in adulthood. Secundum ASD (ostium secundum, most common, 70%) is suitable for transcatheter device closure if anatomy is favorable (adequate rims, size <38–40 mm). Surgical patch repair is used for other types (ostium primum, sinus venosus, coronary sinus ASD). Patent ductus arteriosus (PDA) in preterm infants (<28 weeks, <1000 g) causes a continuous machinery murmur, bounding pulses, wide pulse pressure, and contributes to RDS/BPD, pulmonary edema, NEC, and IVH. Medical closure: IV indomethacin (0.1–0.2 mg/kg q12–24h, 3 doses) or ibuprofen (10 mg/kg then 5 mg/kg at 24 and 48 hours). Surgical ligation if medical therapy fails or is contraindicated (thrombocytopenia, NEC, renal failure). In term infants, PDA is usually small and can be closed via transcatheter device closure. Coarctation of the aorta: discrete narrowing, typically in the juxtaductal region (near the insertion of the ductus arteriosus). Presentation: upper extremity hypertension, diminished/delayed femoral pulses (radiofemoral delay), blood pressure gradient ≥20 mmHg between right arm and legs, and CXR shows rib notching (from collateral circulation) in older children. Infants with critical coarctation present with shock and lower extremity cyanosis when the ductus closes (PGE1 is life-saving as it re-opens the ductus, providing blood flow to the descending aorta). Associated conditions: bicuspid aortic valve (50–85%), VSD, Turner syndrome, and cerebral aneurysms. Treatment: surgical (end-to-end anastomosis, subclavian flap, or prosthetic patch) in infancy; balloon angioplasty with or without stent placement for older children and adolescents with discrete or recurrent coarctation. Long-term follow-up is needed as hypertension and recoarctation can occur.

Tetralogy of Fallot (TOF) is the most common cyanotic CHD, comprising 5–10% of all CHD. The four components are: VSD (large, non-restrictive), right ventricular outflow tract obstruction (RVOTO, most commonly infundibular/pulmonary stenosis, can be valvar or branch PA stenosis), overriding aorta (aortic root dextroposition, usually >50% over the RV), and right ventricular hypertrophy (RVH, secondary to RVOTO). Clinical presentation depends on the degree of RVOTO. Mild RVOTO: acyanotic, loud systolic ejection murmur at LUSB. Severe RVOTO: cyanosis from birth, especially during crying/feeding. Hypercyanotic (tet) spells occur when RVOTO acutely worsens, increasing right-to-left shunting. Triggers: crying, feeding, defecation, fever, hypovolemia. Pathophysiology: infundibular spasm increases RVOTO, decreases pulmonary blood flow, increases R-to-L shunt, worsens cyanosis, causing metabolic acidosis which further increases infundibular spasm. Management of tet spell: knee-chest position (increases SVR), oxygen, morphine 0.1–0.2 mg/kg (decreases agitation, may relax infundibulum), IV normal saline bolus 20 mL/kg (increases preload). If refractory: IV propranolol 0.1–0.2 mg/kg or esmolol (beta-blockers relax infundibular spasm), IV phenylephrine (0.5–5 mcg/kg/min) to increase SVR, ketamine for sedation, general anesthesia if needed. Emergent surgical consultation. Surgical repair: complete intracardiac repair between 3–6 months (patch closure of VSD + RVOTO resection/transannular patch). Some centers perform staged repair with a modified BT shunt if the infant is too small or has unfavorable anatomy. Transposition of the great arteries (TGA) is the most common cyanotic CHD presenting in the first day of life. The aorta arises from the RV and the pulmonary artery from the LV (ventriculoarterial discordance). Survival depends on mixing via ASD, VSD, or PDA. TGA with intact ventricular septum (most common) presents with profound cyanosis at birth. Immediate management: PGE1 infusion to maintain ductal patency, then balloon atrial septostomy (Rashkind procedure) to enlarge the ASD and improve mixing. Definitive repair: arterial switch operation (Jatene procedure) within the first 2 weeks of life. Truncus arteriosus: a single vessel from the heart giving rise to the systemic, pulmonary, and coronary arteries, always associated with a VSD. Presents with CHF and mild cyanosis in the first weeks of life. Pulmonary vascular resistance drops → torrential pulmonary blood flow → CHF. Type I (most common): a single main pulmonary artery arises from the truncus. Management: medical treatment for CHF, then complete repair (RV-to-PA conduit + VSD closure) in the neonatal period. TAPVR (total anomalous pulmonary venous return): pulmonary veins drain into the systemic venous system (right atrium, SVC, IVC, portal system) rather than the left atrium, creating an obligatory right-to-left shunt. Survival requires an ASD (or PFO). Obstructed TAPVR (pulmonary venous obstruction, often infradiaphragmatic) presents with severe cyanosis, pulmonary edema, and respiratory distress at birth, requiring emergent surgical repair. Tricuspid atresia: absence of tricuspid valve with hypoplastic RV. Requires ASD (obligatory R-to-L shunt) and PDA or VSD for pulmonary blood flow. Staged palliation: modified BT shunt (3–6 months), Glenn shunt (bidirectional cavopulmonary shunt at 4–6 months), and Fontan completion (12–36 months). Hypoplastic left heart syndrome (HLHS): underdeveloped LV, aortic atresia/stenosis, and mitral atresia/stenosis. Ductal-dependent systemic circulation. Staged surgical palliation (Norwood, Glenn, Fontan) or heart transplantation.

Innocent (functional) murmurs are extremely common in children and are caused by normal blood flow patterns; they are never associated with cardiac dysfunction or cyanosis. Still murmur is the most common innocent murmur in children 2–7 years, described as a low-pitched, vibratory, musical, or twanging systolic murmur at the LLSB, grade I–III/VI, best heard supine and louder with exercise, fever, or anxiety, disappearing when sitting upright (due to decreased preload). Pulmonary flow murmur is a systolic ejection murmur at the LUSB, often radiating to both lung fields, heard in children with thin chest walls (also in fever, anemia, hyperthyroidism). Venous hum is a continuous soft, low-pitched humming sound in the infraclavicular and supraclavicular area (right > left), louder when sitting upright (different from PDA), and disappears when lying supine or with jugular compression. Carotid bruit is a short systolic bruit over the carotid arteries in young children. Features suggesting a pathologic murmur: murmur ≥III/VI (loud), holosystolic or diastolic (any diastolic murmur is pathologic), associated with a thrill, abnormal S2 (fixed split in ASD, loud single S2 in truncus arteriosus or pulmonary hypertension), ejection click (bicuspid aortic valve, pulmonary valve stenosis), widely split S2 with loud pulmonary component (pulmonary hypertension), opening snap (mitral stenosis), presence of cyanosis, clubbing, or CHF, radiation to the back (coarctation, pulmonary artery stenosis), increase in intensity during Valsalva or standing (hypertrophic cardiomyopathy). In children with suspected pathologic murmur, referral for echocardiography is indicated. Congestive heart failure (CHF) in infants presents differently from adults: tachypnea, poor feeding (tires easily, takes 30+ minutes per feeding), diaphoresis with feeds (especially on the mothers arm), hepatomegaly, cardiomegaly on CXR, and failure to thrive. In older children: dyspnea on exertion, orthopnea, PND, exercise intolerance, peripheral edema, ascites, easy fatigability. Etiology: structural heart disease (large left-to-right shunt, obstructive lesions), arrhythmias (supraventricular tachycardia), myocarditis (viral: enterovirus, Coxsackie B, parvovirus B19, influenza), cardiomyopathy (dilated, hypertrophic, restrictive), Kawasaki disease, and high-output states (severe anemia, thyrotoxicosis). Acute management: furosemide (1–2 mg/kg IV), supplemental oxygen, inotropic support (milrinone, dobutamine, dopamine), and mechanical ventilation for respiratory failure. Chronic management: furosemide or hydrochlorothiazide, ACEi (captopril in infants, enalapril in older children), and beta-blockade (carvedilol) for dilated cardiomyopathy. Surgical correction of the underlying structural heart disease is the definitive treatment.

Acute rheumatic fever (ARF) is a delayed autoimmune reaction following Group A streptococcal pharyngitis in children 5–15 years. The modified Jones criteria (2015 revision for high-risk populations, AHA) require evidence of antecedent GAS infection (throat culture positive, elevated or rising ASO/anti-DNase B titers, or recent scarlet fever) plus 2 major criteria OR 1 major + 2 minor criteria. Major criteria: carditis (most common in younger children, clinical or subclinical valvulitis on echo, mitral regurgitation is most common, followed by aortic; can cause pericarditis and CHF), polyarthritis (migratory, involving large joints: knees, ankles, wrists, elbows; exquisitely tender, dramatic response to NSAIDs), Sydenham chorea (EM picture: involuntary, irregular, jerky, purposeless movements of the face, tongue, and extremities; emotional lability; resolves over weeks to months; may present months after the initial GAS infection), erythema marginatum (evanescent, serpiginous, non-pruritic rash on trunk and inner surfaces of limbs, spares the face), and subcutaneous nodules (small, painless, mobile nodules on extensor surfaces of elbows, knees, wrists, and occiput; rare and associated with severe carditis). Minor criteria: fever ≥38.5C, arthralgia (if no arthritis as a major), elevated ESR/CRP, and prolonged PR interval on ECG (first-degree AV block). Treatment: penicillin or amoxicillin for 10 days to eradicate GAS. Carditis: prednisone 1–2 mg/kg/day for 2–4 weeks then taper, with aspirin/NSAIDs for arthritis. CHF: furosemide, digoxin, ACEi, surgical valve repair/replacement in severe acute valvulitis. Arthritis: high-dose aspirin (80–100 mg/kg/day) or naproxen. Chorea: supportive care; severe cases may benefit from valproate, carbamazepine, or haloperidol. Secondary prophylaxis (to prevent recurrent ARF): penicillin G benzathine IM every 4 weeks (or every 3 weeks for high-risk) OR penicillin V 250 mg PO BID. Duration: minimum 10 years or until age 21, whichever is longer; for severe carditis (valve disease), continue until age 40 or lifelong. Infective endocarditis (IE) prophylaxis (2017 AHA/AAP) is indicated before dental procedures for the highest-risk patients: prosthetic valves, previous IE, unrepaired cyanotic CHD, completely repaired CHD with prosthetic material within 6 months, repaired CHD with residual shunt/valve regurgitation adjacent to prosthetic material, and cardiac transplant valvulopathy. Prophylaxis: amoxicillin 50 mg/kg PO (max 2 g) or ampicillin/cefazolin/ceftriaxone IV; if penicillin-allergic, clindamycin 20 mg/kg or azithromycin 15 mg/kg. Hypercyanotic spells in TOF are life-threatening and require immediate intervention as described above, followed by definitive surgical correction.

Asthma is the most common chronic disease of childhood, affecting approximately 8–10% of children in the US, with a higher prevalence in boys (prepubertal) and Black and Puerto Rican populations. Diagnosis in children ≥5 years is based on symptoms (recurrent wheezing, cough, chest tightness, or dyspnea worse at night, in the early morning, with exercise, or in response to triggers such as viral infections, allergens, cold air, smoke, strong emotions) PLUS demonstration of reversible airflow obstruction on spirometry: FEV1/FVC <0.85 (lower limit of normal in children) with ≥12% improvement in FEV1 after bronchodilator or ≥10% predicted increase; or airway hyperresponsiveness on methacholine or exercise challenge. In children <5 years, diagnosis is made clinically (patterns of cough/wheeze with viral infections, between well-child visits, family history of asthma, personal history of atopy/eczema). Asthma severity is classified (NAEPP EPR-4 and GINA 2025) after stepping down therapy. Step therapy approach (GINA): Step 1 — as-needed low-dose ICS-formoterol (maintenance and reliever therapy, MART) for very mild asthma (symptoms <2/month, no exacerbations). Step 2 — low-dose ICS-formoterol as MART (preferred) or as-needed low-dose ICS + as-needed SABA. Step 3 — low-dose ICS-formoterol MART (preferred) or medium-dose ICS MART. Step 4 — medium-dose ICS-formoterol MART plus add-on LAMA (tiotropium) or LTRA. Step 5 — high-dose ICS-formoterol MART with LAMA and/or biologic therapy (anti-IgE omalizumab for allergic [≥6yr, IgE 30–1500 IU/mL, perennial aeroallergen sensitivity]; anti-IL5 mepolizumab [≥6yr, eosinophilic, ≥150 cells/μL] or benralizumab [≥12yr, eosinophilic]; anti-IL4R dupilumab [≥6yr, eosinophilic]; anti-TSLP tezepelumab [≥12yr, regardless of phenotype]) and/or low-dose OCS. Spacer devices should always be used with metered-dose inhalers to improve drug deposition and reduce oropharyngeal side effects. Peak flow monitoring is recommended for home management in moderate-severe asthma.

Acute asthma exacerbations are episodes of progressive increase in wheezing, cough, chest tightness, and dyspnea that may be accompanied by respiratory distress and hypoxemia. Severity assessment: mild (can talk, SpO2 >95%, no accessory muscle use), moderate (speaks in phrases, SpO2 90–95%, uses accessory muscles, intercostal retractions), severe (speaks in words, SpO2 <90%, exhausted, marked retractions, nasal flaring, paradoxical breathing, audible wheezing or silent chest, bradycardia or poor respiratory effort). Management: inhaled SABA (albuterol: 4–10 puffs via MDI+spacer q20min for 3 doses, or 2.5–5 mg nebulized q20min for 3 doses). Ipratropium bromide (0.25–0.5 mg or 4–8 puffs) is added to SABA for moderate-severe exacerbations (reduces hospitalization risk by 30%). Systemic corticosteroids are the mainstay: dexamethasone 0.6 mg/kg (max 16 mg) PO/IV ×1–2 days or prednisone/prednisolone 1–2 mg/kg/day (max 60 mg) for 3–5 days. For severe exacerbations not responding to initial therapy: continuous albuterol nebulization (10–20 mg/hour), IV magnesium sulfate 25–75 mg/kg (max 2 g), IV terbutaline or aerosolized epinephrine. Impending respiratory failure: altered mental status, cyanosis, silent chest, exhaustion, PaCO2 normal or elevated (ominous sign, indicates respiratory muscle fatigue and impending arrest). These patients require ICU admission, BiPAP or intubation, and mechanical ventilation. Asthma action plans (written, color-coded: green, yellow, red zones) reduce emergency visits and hospitalizations. Biologics have dramatically reduced exacerbations in severe persistent asthma.

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CFTR gene located on chromosome 7q31.2, which encodes the cystic fibrosis transmembrane conductance regulator, a chloride channel in epithelial cells. Over 2000 CFTR mutations have been identified; F508del (c.1521_1523delCTT, Phe508del) is the most common, accounting for >70% of CF alleles in Caucasians. Class I–VI mutations affect CFTR synthesis, processing, gating, conductance, and stability. CF incidence is approximately 1 in 3500 live births among Caucasians, less common in African and Asian populations. Diagnosis is established by: newborn screening (elevated immunoreactive trypsinogen IRT on blood spot, followed by CFTR mutation analysis), followed by a sweat chloride test (gold standard). Sweat chloride ≥60 mmol/L confirms CF; 30–59 mmol/L is intermediate and requires further evaluation (expanded CFTR sequencing, nasal potential difference measurement). Pulmonary disease is the major cause of morbidity and mortality. Thick, tenacious secretions lead to impaired mucociliary clearance, chronic bacterial infection, and an intense neutrophilic inflammatory response, ultimately causing progressive bronchiectasis. Most common pathogens: Staphylococcus aureus (early childhood, including MRSA), Haemophilus influenzae, Pseudomonas aeruginosa (mucoid phenotype is pathognomonic, associated with declining lung function), Stenotrophomonas maltophilia, Achromobacter xylosoxidans, nontuberculous mycobacteria (especially M. abscessus), and Aspergillus fumigatus (may cause allergic bronchopulmonary aspergillosis ABPA). Management of pulmonary disease: airway clearance techniques (chest physiotherapy with percussion/postural drainage in infants, high-frequency chest wall oscillation Vest, positive expiratory pressure PEP/Flutter/Acapella, autogenic drainage, and exercise), mucolytics (dornase alfa/Pulmozyme daily, recombinant DNase, degrades neutrophil-derived DNA in mucus, improves FEV1 by 6–10%), hypertonic saline (7% inhaled BID, increases mucociliary clearance), bronchodilators (albuterol before airway clearance), and chronic azithromycin (3 times/week, anti-inflammatory and anti-Pseudomonas effects). Acute pulmonary exacerbations: increased cough, sputum production, dyspnea, decreased FEV1, weight loss, fever. Treatment: 14–21 days of IV antibiotics (dual coverage for Pseudomonas: beta-lactam such as ceftazidime or meropenem, PLUS aminoglycoside or fluoroquinolone; adjust based on susceptibility). CFTR modulator therapies are disease-modifying: ivacaftor (Kalydeco) for gating mutations (G551D, others), lumacaftor-ivacaftor (Orkambi) for F508del homozygotes, tezacaftor-ivacaftor (Symdeko) for F508del and residual function, and elexacaftor-tezacaftor-ivacaftor (Trikafta) for F508del + minimal function mutation (90% of CF population). Trikafta improves FEV1 by 10–15%, reduces pulmonary exacerbations by 60–70%, improves weight/BMI, and lowers sweat chloride into the intermediate/ normal range. Gastrointestinal manifestations: pancreatic insufficiency (PI) in 85–90% (requires pancreatic enzyme replacement therapy PERT 500–4000 units lipase/g fat, taken with all meals and snacks), fat-soluble vitamin deficiency (ADEK supplementation), meconium ileus (10–20% of newborns, non-passage of meconium, may require Gastrografin enema or surgical resection), distal intestinal obstruction syndrome (DIOS, partial/complete obstruction in the terminal ileum/ascending colon, treat with osmotic laxatives, enemas), CF-related liver disease (focal biliary cirrhosis, UDCA therapy), and CF-related diabetes (CFRD, 20–30% of adults, combination of insulin deficiency and resistance, managed with insulin therapy not oral agents). Lung transplantation is an option for end-stage lung disease, with 5-year survival ~50–60%.

Foreign body aspiration (FBA) is most common in children 6 months to 3 years (peak 1–2 years). Common aspirated objects: peanuts, seeds, hot dogs, popcorn, raw carrots, grapes, hard candy, small toy parts, coins, and balloon fragments (most fatal). The classic triad (sudden onset of coughing, choking, and wheezing) is present in only 30–50% of cases. Presentation depends on location: laryngeal/tracheal FB causes stridor, hoarseness, croup-like cough, and cyanosis; bronchial FB (right mainstem more common due to wider angle and higher flow) causes unilateral wheeze, decreased breath sounds, and cough; chronic FB causes persistent cough, recurrent pneumonia, lung abscess, or bronchiectasis. Initial CXR (inspiratory-expiratory or bilateral decubitus) shows air trapping (hyperinflation on the affected side from ball-valve effect causing obstructive emphysema), mediastinal shift away from the obstructed side, atelectasis (complete obstruction with resorption of air), or a radiopaque FB (only 10% of objects are radiopaque, so a negative CXR does NOT exclude FB). Rigid bronchoscopy is the gold standard for diagnosis and removal. Post-bronchoscopy: monitor for edema (racemic epinephrine), subglottic stenosis, pneumonia. Tracheoesophageal fistula (TEF) with esophageal atresia (EA): most common is Type C (EA with distal TEF, 85%). Infants present with excessive drooling, choking, coughing, cyanosis with feeds, inability to pass an NG tube (coils in the upper pouch). CXR shows NG tube coiled in the upper esophageal pouch and gas in the stomach (from distal TEF). Initial management: NPO, Replogle tube for continuous suction, upright positioning. Surgical repair: fistula ligation + primary esophageal anastomosis. VACTERL association is present in 25–30% of TEF/EA cases. Congenital diaphragmatic hernia (CDH): Bochdalek (posterolateral) hernia, 85–90% left-sided. Presents with respiratory distress at birth, scaphoid abdomen, bowel sounds in the chest, CXR showing bowel loops in the hemithorax with mediastinal shift. Associated pulmonary hypoplasia and pulmonary hypertension. Management: gentle ventilation (permissive hypercapnia, low peak pressures <25 cmH2O, avoid pneumothorax), HFOV if needed, inhaled nitric oxide for PPHN, ECMO as rescue, and delayed surgical repair after stabilization. Sleep-disordered breathing: obstructive sleep apnea (OSA) in children is most commonly caused by adenotonsillar hypertrophy. Symptoms: loud snoring, witnessed apneas, restless sleep, mouth breathing, enuresis, daytime neurobehavioral problems (ADHD-like symptoms, poor school performance, morning headache). Polysomnography (PSG) is gold standard: AHI ≥1.5 is abnormal in children. Treatment: adenotonsillectomy (first-line, >80% effective), CPAP/BiPAP if residual or contraindication to surgery, INCS for mild SDB with AR, weight management for obesity.

Chronic cough (>4 weeks) in children requires a systematic approach. Most common etiologies: cough-variant asthma (nighttime, with exercise, triggers), protracted bacterial bronchitis (PBB: wet/moist cough >4 weeks, responds to 2–4 weeks of amoxicillin-clavulanate, thought to be from bacterial biofilm infection in the airways), upper airway cough syndrome/postnasal drip from allergic rhinitis, GERD, and foreign body aspiration (suspect especially if acute onset of cough). Less common: cystic fibrosis, primary ciliary dyskinesia (Kartagener triad: situs inversus, sinusitis, bronchiectasis; low nasal NO; biopsy shows ciliary ultrastructural defects), bronchiectasis from immunodeficiency or post-infectious, interstitial lung disease (chILD), aspiration syndromes (oropharyngeal dysphagia, GERD, H-type TEF), tracheomalacia, and psychogenic cough (barking/honking cough, disappears when asleep, responds to suggestion therapy). Chest XR is first-line. Spirometry should be attempted in children ≥5–6 years. PFT interpretation uses lower limits of normal (LLN) from GLI-2012 equations: obstructive pattern (FEV1/FVC <LLN), restrictive pattern (FVC <LLN with normal FEV1/FVC), mixed pattern. Bronchodilator response: ≥12% improvement in FEV1 or ≥10% predicted. FeNO (fractional exhaled nitric oxide) >35 ppb suggests eosinophilic airway inflammation (asthma, allergic rhinitis). Impulse oscillometry (IOS) is a useful alternative for uncooperative children. Allergic rhinitis (AR) is a common comorbidity of asthma, affecting up to 40% of children. Diagnosis (clinical + skin prick testing or sIgE). Treatment: INCS (fluticasone, mometasone, triamcinolone) first-line; second-generation oral antihistamines (cetirizine, levocetirizine, fexofenadine, loratadine); intranasal antihistamines (azelastine, olopatadine); montelukast (nocturnal symptoms, but boxed warning for neuropsychiatric events); allergen immunotherapy (SCIT or SLIT) for moderate-severe uncontrolled with medications. Good AR control improves asthma control.

Gastroesophageal reflux (GER) is the normal physiologic passage of gastric contents into the esophagus in healthy infants, occurring in >50% of infants <3 months. Physiologic GER peaks at 4 months of age and resolves spontaneously by 12–18 months as the lower esophageal sphincter matures and the infant transitions to upright posture and solid foods. It presents as effortless, non-bilious regurgitation shortly after feeds in a happy, thriving infant. GERD (gastroesophageal reflux disease) occurs when reflux causes troublesome symptoms or complications. Distinguishing features: irritability, arching of the back (Sandifer syndrome, often misinterpreted as seizures), excessive crying, refusal to feed, poor weight gain/FTT, hematemesis, chronic cough/wheezing, recurrent aspiration pneumonia, laryngitis, hoarseness, and apparent life-threatening events (ALTEs, now termed BRUE). In older children and adolescents, symptoms resemble adult GERD (heartburn, epigastric pain, dysphagia, regurgitation). Diagnostic workup is reserved for suspected GERD with red flags or atypical presentation: upper GI series (to rule out anatomic abnormalities: malrotation, hiatal hernia, pyloric stenosis, TEF), esophageal pH/impedance monitoring (gold standard for quantifying acid and non-acid reflux, especially when symptoms correlate poorly with reflux events), and EGD with biopsies (to evaluate for eosinophilic esophagitis, esophagitis, Barrett esophagus; histology shows eosinophils ≥15/HPF in EoE, basal hyperplasia, and papillary elongation in GERD). Management of physiologic GER: parental reassurance, avoid overfeeding, upright positioning after feeds (but NOT in a car seat carrier which increases intra-abdominal pressure; flat supine for sleep per SIDS guidelines), and thickened feeds (1 tbsp rice cereal per 1–2 oz formula or expressed breast milk). For GERD: trial of acid suppression. First-line: PPI (omeprazole 1–3 mg/kg/day, lansoprazole 1–2 mg/kg/day, esomeprazole 1–3 mg/kg/day) for 4–8 weeks. H2RAs (famotidine 1–2 mg/kg/day) are second-line due to tachyphylaxis. Prokinetics (metoclopramide, erythromycin) are NOT recommended due to limited efficacy and significant side effects (dystonic reactions, QTc prolongation, cardiac arrhythmias). For severe GERD refractory to medical therapy with complications (aspiration, esophagitis, FTT), Nissen fundoplication may be considered, though long-term outcomes are mixed.

Hypertrophic pyloric stenosis (HPS) has an incidence of 2–4 per 1000 live births, with a strong male predominance (4–5:1 M:F), and is more common in first-born males. It presents at 2–8 weeks of age (peak 3–5 weeks) with non-bilious, projectile vomiting that occurs immediately after or within 30 minutes of feeding. The classic infant is hungry and feeds avidly after vomiting (voracious feeder). Physical findings: visible peristaltic waves (moving left to right across the epigastrium), and a palpable olive-shaped mass in the RUQ (hypertrophied pyloric muscle, best felt with the infant relaxed, knees flexed, while feeding or after vomiting). The classic electrolyte disturbance is hypochloremic, hypokalemic metabolic alkalosis (loss of HCl and K from gastric fluid). In prolonged vomiting, the kidney attempts to conserve HCO3 and Na, leading to paradoxical aciduria (initially acidic urine despite metabolic alkalosis, later changes to alkaline urine in severe cases). Ultrasound is the diagnostic modality of choice: pyloric muscle thickness ≥3.5–4 mm (most centers use ≥4 mm as diagnostic), pyloric length ≥15–19 mm, and pyloric diameter ≥10–14 mm. Initial management: NPO, IV fluid resuscitation with normal saline 20 mL/kg boluses to correct dehydration and metabolic alkalosis before surgery. Once potassium is confirmed normal (and the infant is producing urine), add KCl to maintenance fluids (D5 1/2NS + 20 mEq/L KCl). Surgical correction: Ramstedt pyloromyotomy (laparoscopic or open) is the definitive treatment, where the hypertrophied pyloric muscle is incised longitudinally down to the submucosa, without entering the lumen. Post-operative feeding can begin 4–6 hours after surgery: start with small volumes (15–30 mL) of electrolyte solution, advance to full-strength formula/breast milk over 24–48 hours. Some post-operative vomiting is common and resolves within 24–48 hours due to gastric edema and atony. Prognosis is excellent with near-zero mortality in developed countries.

Intussusception is the invagination (telescoping) of one segment of bowel (the intussusceptum) into the adjacent distal segment (the intussuscipiens), most commonly ileocolic (85%), but can be ileoileal, ileocecocolic, or colocolic. Peak incidence is 3–36 months (most common at 5–9 months). The classic presentation is the triad of colicky abdominal pain (child draws up legs and screams in pain, occurring in waves every 15–20 minutes), currant jelly stools (mixture of blood and mucus indicating ischemic bowel, a late sign), and a palpable sausage-shaped RUQ mass on abdominal exam. However, the classic triad is present in only 20–30%; many children present with vomiting, lethargy (sometimes extreme, alternating with normal periods), or episodic irritability. Ultrasound is the diagnostic imaging of choice (sensitivity >98%, specificity >98%), showing the target sign (concentric rings, donut) on transverse view and the pseudo-kidney sign on longitudinal view. Abdominal XR may show a soft tissue density mass, paucity of bowel gas in the RUQ, or obstruction; it should NOT be used to exclude intussusception if clinical suspicion is high (false negative rate up to 50%). Treatment: air enema (or contrast enema) is both diagnostic and therapeutic; it is the first-line treatment in hemodynamically stable children without peritonitis or pneumoperitoneum. The radiologist insufflates air or instills contrast into the colon under fluoroscopic or US guidance; the intussusceptum is reduced as the pressure pushes it back proximal. Success rates: 80–95% with air enema. Contraindications to enema reduction: pneumoperitoneum (perforation, peritonitis), shock, or suspected necrotic bowel. After successful reduction, the child is admitted for observation (24 hours); recurrence rate is <10%. Surgical management is indicated if: enema reduction fails, peritonitis or perforation is present, a pathologic lead point is suspected (Meckel diverticulum, polyp, duplication cyst, lymphoma, HSP), or recurrent intussusception (>2–3 episodes). Surgery: laparoscopy or laparotomy with manual reduction, or bowel resection if the bowel is necrotic or a lead point is found.

Hirschsprung disease is a congenital disorder characterized by the absence of ganglion cells (parasympathetic intrinsic neurons) in the distal colon, extending proximally from the internal anal sphincter. This occurs due to failure of neural crest cell migration during embryogenesis (weeks 5–12 of gestation). The aganglionic segment is most commonly rectosigmoid (80%), followed by long-segment (15–20%), total colonic (3–5%), and rare total intestinal aganglionosis. The classic presenting sign in the newborn period is failure to pass meconium within 48 hours of birth (99% of term infants pass meconium by 48 hours; failure is a major red flag). Other manifestations: abdominal distension, bilious vomiting, feeding intolerance, and enterocolitis (explosive, foul-smelling diarrhea, fever, abdominal distension, septic shock, toxic megacolon). In older infants and children: severe chronic constipation since birth, abdominal distension, ribbon-like stools, failure to thrive, and recurrent enterocolitis. On physical exam, the rectal vault is empty (spastic aganglionic segment) on digital rectal exam, which may be followed by a gush of stool and gas (squirt sign). Diagnosis is confirmed by rectal suction biopsy demonstrating the absence of ganglion cells in the submucosal plexus (Meissner plexus) and the presence of hypertrophied, thick nerve trunks with positive acetylcholinesterase staining. Anorectal manometry shows absence of the rectoanal inhibitory reflex (RAIR). Contrast enema shows a transition zone with a cone-shaped or funnel-shaped appearance between the narrow aganglionic distal segment and the dilated proximal ganglionic bowel. However, this may be absent in neonates and in total colonic aganglionosis (where the colon appears as a short colon or microcolon). Initial management (pre-operative): rectal irrigations (warmed normal saline 10–20 mL/kg via rectal tube, 2–4 times daily) to decompress the bowel and prevent enterocolitis. Definitive treatment: pull-through surgery (resection of the aganglionic segment with anastomosis of ganglionic bowel to the anus), performed at 1–3 months of age. Three main surgical approaches: Soave (endorectal pull-through), Swenson (abdominoperineal pull-through), and Duhamel (retrorectal pull-through). Laparoscopic approaches are now common. Post-operative complications: Hirschsprung-associated enterocolitis (HAEC, most common and most serious, 20–40% even after pull-through; presents with fever, explosive diarrhea, distension, lethargy; treatment: NPO, rectal irrigations, IV antibiotics), soiling/incontinence (from anal sphincter dysfunction or retained aganglionic segment), constipation, and anastomotic stricture. Long-term outcomes are generally good, though some children may have persistent constipation or soiling into adolescence.

Celiac disease is an immune-mediated enteropathy triggered by dietary gluten (the protein found in wheat, barley, and rye) in genetically predisposed individuals with HLA-DQ2 (90–95%) or HLA-DQ8 (5–10%). The prevalence is approximately 1% globally, with significant underdiagnosis. The pathogenesis involves deamidation of gluten by tissue transglutaminase (tTG), which is then presented by HLA-DQ2/DQ8 to CD4+ T cells, activating a Th1 immune response that produces IFN-gamma and drives villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis. Clinical presentation varies by age. Classic presentation in infants/toddlers (6–24 months): chronic diarrhea, abdominal distension, vomiting, failure to thrive, muscle wasting, irritability. Older children and adolescents: atypical/extraintestinal presentation with iron deficiency anemia (refractory to oral iron), short stature, delayed puberty, dental enamel hypoplasia (symmetrical pitting of permanent incisors and molars), dermatitis herpetiformis (intensely pruritic vesiculobullous rash on extensor surfaces, elbows, knees, buttocks, and scalp), arthralgia, elevated transaminases (cryptogenic hypertransaminasemia), chronic fatigue, and neurologic symptoms (ataxia, peripheral neuropathy, headache, epilepsy with occipital calcifications). Associated conditions: type 1 diabetes (3–8% have celiac), Down syndrome (∼5%), Turner syndrome, Williams syndrome, IgA deficiency, autoimmune thyroiditis, Sjogrens syndrome, and IgA nephropathy. Screening: first-degree relatives of celiac patients (5–15% risk) and all with associated conditions should be screened. Serologic testing: tTG-IgA (tissue transglutaminase antibody) plus total IgA (to rule out selective IgA deficiency, which is 10–15 times more common in celiac). If tTG-IgA is ≥10 times the upper limit of normal, the positive predictive value for celiac is >95% in symptomatic children, and some guidelines (ESPGHAN 2020) permit diagnosis without biopsy in this scenario. For less elevated tTG-IgA, confirmatory EGD with multiple duodenal biopsies (at least 4 from D2 and 2 from the duodenal bulb) is required. Histology is graded by the Marsh classification: Marsh 0 (normal), Marsh 1 (>25 intraepithelial lymphocytes per 100 enterocytes), Marsh 2 (crypt hyperplasia), Marsh 3 (villous atrophy: A = partial, B = subtotal, C = total). HLA testing (DQ2/DQ8) has a high negative predictive value (>99%) and can effectively rule out celiac disease. Treatment: strict lifelong gluten-free diet (GFD). Foods to avoid: wheat (all varieties: durum, spelt, farro, semolina, kamut, einkorn, graham), barley, rye, triticale, and cross-contaminated oats (pure, uncontaminated oats are safe for most celiac patients, but 5–10% react to avenin). Safe grains: rice, corn, quinoa, sorghum, millet, buckwheat, amaranth, teff, and certified gluten-free oats. Response to GFD: symptoms improve within days to weeks; serology (tTG-IgA) declines and should normalize within 6–12 months (non-normalization suggests poor dietary compliance). Follow-up: tTG-IgA every 6–12 months to monitor compliance; consider repeat EGD with biopsies for non-responders. Nutritional deficiencies to monitor: iron, folate, vitamin B12, vitamin D, calcium, zinc. Long-term complications of untreated or poorly controlled disease: osteoporosis (from malabsorption of calcium and vitamin D), infertility (both sexes), and intestinal lymphoma (enteropathy-associated T-cell lymphoma EATL, rare <1% lifetime risk). Vaccination: pneumococcal vaccine is recommended due to risk of hyposplenism in poorly controlled disease.

Acute gastroenteritis (AGE) is defined as ≥3 loose or watery stools and/or ≥2 episodes of vomiting in a 24-hour period, caused by infectious agents. Viral pathogens predominate: rotavirus (most common cause of severe AGE in infants before vaccine introduction, now norovirus may be the leading cause), norovirus (all ages, outbreaks in settings), adenovirus (types 40/41), astrovirus, and sapovirus. Bacterial causes: Shigella, Salmonella, Campylobacter, enterotoxigenic E. coli (ETEC), enterohemorrhagic E. coli (EHEC/STEC O157:H7), Yersinia, and C. difficile. Parasitic: Giardia lamblia, Cryptosporidium. Rotavirus vaccines (RotaTeq [RV5, 3-dose] and Rotarix [RV1, 2-dose]) given at 2 and 4 months have reduced rotavirus hospitalizations by >80% in the US. Dehydration severity assessment is critical and guides therapy. The WHO Integrated Management of Childhood Illness (IMCI) classification: no signs of dehydration (<3% body weight loss, less than 2 of: restless/irritable, sunken eyes, drinks eagerly/thirsty, skin pinch slow), some dehydration (3–8% loss, 2 or more of these signs), severe dehydration (>8–10% loss, 2 or more of: lethargic/unconscious, very sunken eyes, unable to drink/drinks poorly, skin pinch very slow ≥2 seconds). Weight change is the best objective measure of fluid deficit. Clinical signs: mild (<3%): normal or slightly decreased urine output, slightly dry mucous membranes, normal heart rate, normal blood pressure. Moderate (3–8%): decreased urine output, dry mucous membranes, sunken eyes, decreased skin turgor, tachycardia, delayed capillary refill (>2 seconds). Severe (>8–10%): oliguria or anuria, very dry mucous membranes, very sunken eyes, tenting skin turgor, tachycardia, hypotension (late sign, indicates imminent shock), lethargy, mottled extremities, weak thready pulses. Laboratory evaluation is not routinely needed but is indicated for severe dehydration, complicated or prolonged course, or shock: BMP (electrolytes, BUN, Cr), VBG (metabolic acidosis), and stool culture (for bloody/mucoid stools, travel, immunocompromised, daycare exposure, suspected HUS). The cornerstone of management is oral rehydration therapy (ORT) using low-osmolarity oral rehydration solution (ORS: Na 45–75 mEq/L, glucose 2–2.5%, osmolarity ≤250 mOsmol/L) at 50–100 mL/kg over 4–6 hours for some dehydration. For severe dehydration: IV access quickly established, 20 mL/kg NS bolus, repeat until perfusion improves (up to 60 mL/kg). Ondansetron 0.15–0.3 mg/kg IV/PO (max 8 mg) is effective for vomiting and facilitates ORT success. Loperamide is contraindicated in children <3 years or with dysenteric stools. Zinc supplementation 20 mg/day for 10–14 days reduces diarrhea duration and severity in resource-limited settings.

Febrile seizures occur in 2–5% of children aged 6 months to 5 years (peak at 18 months), making them the most common seizure disorder in childhood. They are defined as seizures associated with a fever ≥38.0/100.4F in the absence of intracranial infection, electrolyte imbalance, or a prior history of afebrile seizures. They are categorized as simple (80–90%) or complex (10–20%). Simple febrile seizure: generalized tonic-clonic seizure, lasting <15 minutes, single episode in 24 hours, no post-ictal focal neurologic deficits, normal development and neurologic exam. Complex febrile seizure: focal onset, prolonged (≥15 minutes, up to 30 minutes), multiple seizures within 24 hours, or associated with post-ictal focal deficits (Todds paralysis). Risk factors for febrile seizure: family history of febrile seizures in a first-degree relative (increased 3–4x), developmental delay, daycare attendance (frequent infections), and high fever with rapid temperature rise. The risk of recurrence after a first febrile seizure is 30–40%, with higher risk if age <18 months at first seizure, lower temperature at onset, short duration of fever before seizure, or a positive family history. The risk of developing epilepsy (afebrile seizures) after a simple febrile seizure is only slightly higher (1–2%) than the general population (1%). However, after complex febrile seizures, the risk increases to 4–15%, especially if there are neurodevelopmental abnormalities, prolonged seizure (>15 min), or a family history of epilepsy. Evaluation: the main goal is to identify the source of fever and rule out meningitis. For simple febrile seizures in a child with a clear source of fever, a normal exam, and reassuring immunization status, no further evaluation is required beyond treating the underlying illness. Lumbar puncture is indicated if: meningeal signs are present (neck stiffness, Kernig/Brudzinski sign), the child is <6–12 months of age (higher risk of occult meningitis, signs are unreliable), the child was pretreated with antibiotics before the seizure (which could partially treat meningitis), the seizure is complex with prolonged post-ictal depression or obtundation, or there is a febrile seizure in a child with an uncertain immunization history. An EEG is not routinely indicated after a simple febrile seizure; it may be considered after complex febrile seizures or if there are atypical features. Brain imaging (CT/MRI) is not indicated after a simple febrile seizure. Management: most febrile seizures stop spontaneously before medical attention. Prolonged (>5 minutes) or ongoing seizures should be treated with benzodiazepines (IV lorazepam 0.1 mg/kg, rectal diazepam 0.5 mg/kg, or buccal/intranasal midazolam 0.2–0.3 mg/kg). Fever management with antipyretics (acetaminophen, ibuprofen) improves comfort but does NOT reduce the risk of recurrence. Home rescue medication (rectal diazepam gel or intranasal midazolam) may be prescribed for children with prolonged or frequent febrile seizures. Antiepileptic medication is NOT indicated to prevent simple febrile seizures.

Infantile spasms (West syndrome) presents between 3–12 months (peak 4–6 months) with clusters of brief (1–5 second) symmetric flexor, extensor, or mixed spasms, often occurring in clusters shortly after awakening. The spasms can be easily mistaken for colic, Moro reflex, or startle. The classic EEG finding is hypsarrhythmia (high-voltage, chaotic, asynchronous slow waves with multifocal spikes and sharp waves). Etiologies are divided into structural (malformations of cortical development, tuberous sclerosis, HIE, stroke, genetic), genetic (CDKL5, ARX, STXBP1, KCNQ2), metabolic (PKU, nonketotic hyperglycinemia, mitochondrial disorders), and unknown. The International League Against Epilepsy (ILAE) recommends first-line treatment with ACTH (150 U/m2/day IM for 2 weeks then taper) or high-dose oral prednisolone (4–8 mg/kg/day for 2 weeks then taper) for non-TSC cases. For infantile spasms due to TSC (tuberous sclerosis complex): vigabatrin (150 mg/kg/day) is first-line (superior to ACTH for TSC). Prognosis: 50–70% develop other seizure types and intellectual disability; early treatment improves developmental outcomes. Childhood absence epilepsy (CAE) has a peak onset at 4–8 years, presenting with frequent (dozens to hundreds per day) staring spells lasting 5–20 seconds with abrupt onset and offset, often with eyelid fluttering, mild automatisms, and no post-ictal confusion. The spells may be misinterpreted as daydreaming or inattention by parents and teachers. Hyperventilation for 3–5 minutes reliably provokes absence seizures in untreated children. EEG shows classic generalized 3 Hz spike-and-wave discharges. Treatment: ethosuximide is first-line (most effective for absence-only seizures, fewer side effects), or valproate (if combined generalized tonic-clonic or myoclonic seizures). Lamotrigine is an alternative. Prognosis: 60–80% outgrow seizures by adolescence. Juvenile myoclonic epilepsy (JME) presents at 12–18 years with myoclonic jerks (especially on awakening), generalized tonic-clonic seizures (GTCS, often on awakening), and absence seizures (30%). Myoclonic jerks are often dismissed as clumsiness or nervousness. Triggers: sleep deprivation, alcohol, photic stimulation (video games, strobe lights, flashing screens). EEG shows generalized 4–6 Hz polyspike and wave discharges, often with photosensitivity. First-line treatment for JME is valproate (most effective for all seizure types). For females of childbearing potential: lamotrigine or levetiracetam are alternatives, given the teratogenicity of valproate (neural tube defects, reduced IQ, autism). JME is usually lifelong, but >80% achieve seizure control with appropriate medication.

Cerebral palsy (CP) is a group of permanent, non-progressive disorders of movement and posture caused by a static injury to the developing fetal or infant brain (occurring prenatally, perinatally, or during the first 2–3 years). The prevalence is 2–3 per 1000 live births; the most common risk factors include prematurity (<32 weeks), low birth weight (<1500 g), chorioamnionitis, multiple gestation, intrauterine infection (CMV, toxoplasma, Zika), perinatal asphyxia, kernicterus, and postnatal CNS infection (meningitis, encephalitis) or head trauma. Classification: spastic CP (85%) — hypertonia, hyperreflexia, clonus, spasticity (velocity-dependent increase in tone), and upgoing plantars. Subtypes by distribution: spastic hemiplegia (unilateral, upper extremity > lower, often from middle cerebral artery territory stroke, walking by 2 years, fine motor deficits), spastic diplegia (bilateral, legs > arms, classic in preterm infants with periventricular leukomalacia PVL, scissoring gait, intellectual disability less common), and spastic quadriplegia (all four limbs, most severe, from global hypoxic-ischemic injury, associated with intellectual disability, epilepsy, dysphagia, and visual/hearing impairment). Dyskinetic CP (10–15%): choreoathetosis, dystonia, athetosis, often with preserved cognition, typically from basal ganglia injury (kernicterus, HIE). Ataxic CP (<5%): hypotonia, intention tremor, wide-based gait, and incoordination (cerebellar injury). Mixed CP (10%): combination. Associated impairments: intellectual disability (30–50%, highest in spastic quadriplegia), epilepsy (30–50%), visual impairment (strabismus, refractive errors, cortical visual impairment, hemianopia in hemiplegic CP), hearing loss, speech/language disorders (dysarthria, aphasia), feeding difficulties (dysphagia, GERD, aspiration, drooling, malnutrition), constipation, sleep disorders, and orthopedic complications (hip subluxation/dislocation, scoliosis, contractures). Management is multidisciplinary: physical therapy (strengthening, stretching, gait training, positioning, adaptive equipment, standing frames, orthotics AFOs), occupational therapy (fine motor skills, ADL training, adaptive equipment, splinting), and speech-language therapy (communication, feeding therapy, oral motor skills). Medical management of spasticity: oral baclofen (for generalized spasticity, but causes sedation and weakness), diazepam (short-term for acute exacerbations), tizanidine, and dantrolene. Botulinum toxin type A (Botox) injections are first-line for focal spasticity (especially lower limbs, adductors, gastrocnemius, hamstrings), improving function and gait, reducing pain, and delaying contractures. Intrathecal baclofen pump is used for severe generalized spasticity that is unresponsive to oral therapy. Orthopedic surgery: tendon lengthening (Achilles, hamstrings, adductors), tendon transfers, osteotomies, and scoliosis correction. Selective dorsal rhizotomy (SDR) involves cutting selective sensory nerve roots to reduce spasticity, indicated for carefully selected children with spastic diplegia (good selective motor control, no significant dystonia, good core strength, IQ >70). Hip surveillance: physical exam + X-ray every 6–12 months (starting at 2–3 years) to detect subluxation early (Reimers index >30% warrants surgical consideration). Pain is common in CP (25–75%) and may be related to hip subluxation, spasticity, contractures, GERD, constipation, or dental caries; requires systematic assessment and treatment.

Neural tube defects (NTDs) are congenital malformations resulting from failure of neural tube closure between days 21–28 of embryonic development, before most women know they are pregnant. The most common NTDs are spina bifida (open or closed) and anencephaly (incompatible with life, uniformly fatal). Anencephaly is the absence of the cranial vault and cerebral hemispheres. Myelomeningocele (open spina bifida) is a protrusion of meninges, spinal cord, and nerve roots through a vertebral defect. It is often diagnosed prenatally by elevated maternal serum alpha-fetoprotein (MSAFP >2.0–2.5 MoM at 16–18 weeks gestation), confirmed by fetal ultrasound and/or MRI. The level of the lesion determines the degree of neurologic impairment: higher lesions (thoracic, lumbar) produce more severe weakness (complete paraplegia), sensory loss, bowel/bladder dysfunction (neurogenic bladder requiring clean intermittent catheterization CIC, neurogenic bowel requiring bowel program), and orthopedic deformities (clubfoot, hip dislocation, scoliosis). Chiari II malformation is present in >90% of children with myelomeningocele, characterized by hindbrain herniation through the foramen magnum, causing brainstem compression, central apnea, swallowing dysfunction, vocal cord paralysis, nystagmus, and hydrocephalus (80–90% require VP shunt). Meningocele is less severe: only the meninges (not the spinal cord) herniate. Spina bifida occulta is a closed NTD with a skin-covered vertebral defect, often an incidental finding on XR; may be associated with a cutaneous marker (sacral dimple with depth >5 mm, deviation of gluteal cleft, hemangioma, hairy tuft, or dermal sinus tract). Tethered cord syndrome (fixation of the conus medullaris, often associated with lipoma or diastematomyelia) may present in older children with progressive gait deterioration, weakness, sensory loss, sphincter dysfunction, and back pain. Diagnosis: MRI of the entire spine. Treatment: surgical detethering. Folate supplementation is the most effective prevention strategy: all women of childbearing age should take 400 mcg of folic acid daily in a multivitamin. For women at high risk (prior NTD pregnancy, family history, anti-epileptic medication use [valproate, carbamazepine], maternal diabetes, or celiac/malabsorption), a higher dose of 4–5 mg daily is recommended, starting at least 1 month before conception and continuing through the first trimester. Periconceptional folate supplementation reduces the risk of NTDs by 50–70%.

Headaches are common in children, increasing in prevalence through adolescence. Primary headaches include migraine (with or without aura), tension-type headache, cluster headache, and childhood periodic syndromes (cyclic vomiting, abdominal migraine, benign paroxysmal vertigo of childhood). Migraine in children is often bilateral (frontal or bitemporal rather than unilateral), lasts 1–72 hours, and may be accompanied by pallor, dizziness, and nausea/vomiting. Diagnosis (ICHD-3): ≥5 attacks lasting 1–72h, with ≥2 of: unilateral or bilateral, pulsating, moderate-severe, aggravated by activity; plus ≥1 of: nausea/vomiting, photophobia/phonophobia. Treatment: acute → ibuprofen or acetaminophen, triptans (sumatriptan nasal spray for ≥6yr, rizatriptan ODT for ≥6yr, zolmitriptan for ≥12yr). Prevention → amitriptyline, topiramate, cyproheptadine, propranolol; lifestyle (regular sleep, meals, exercise, hydration, avoid trigger foods, limit caffeine and screen time); and cognitive-behavioral therapy (CBT)/biofeedback. Red flags (SNNOOP10): sudden-onset thunderclap headache, progressive worsening over days-weeks, headache with fever and neck stiffness, headache with papilledema, headache awakening the child from sleep or recurring early morning with vomiting, headache with focal neurologic deficits, headache with seizure, headache with visual disturbances, headache in immunocompromised state, headache with known malignancy, headache with positional component. Acute ataxia: broad differential includes post-infectious acute cerebellar ataxia (most common, usually after varicella, enterovirus, EBV, mycoplasma, presents days to weeks later, self-resolves in weeks), drug intoxication (alcohol, antiseizure, antihistamines), Guillain-Barre syndrome (Miller-Fisher variant: ataxia + opthalmoplegia + areflexia, anti-GQ1b), acute disseminated encephalomyelitis (ADEM: multifocal demyelination with encephalopathy, MRI white matter lesions), brain tumor (posterior fossa: medulloblastoma, cerebellar astrocytoma, brainstem glioma), cerebellar abscess, opsoclonus-myoclonus-ataxia (neuroblastoma, urine VMA/HVA, MRI chest/abdomen, MIBG scan), and metabolic disorders. Evaluation: MRI brain with and without contrast (posterior fossa views), LP (if meningitis or ADEM suspected), urine catecholamines, serum lactate, ammonia, amino acids. Brain tumors in children differ from adults in that they are more commonly infratentorial (posterior fossa). Medulloblastoma: midline cerebellar, highly malignant, peak 5–8yr, presents with morning headache, vomiting, ataxia, and hydrocephalus (shunt required before resection). Cerebellar astrocytoma: benign, surgical resection, good prognosis. Diffuse intrinsic pontine glioma (DIPG): CN deficits (VI, VII), long tract signs, ataxia, headache, very poor prognosis (median survival 9–12mo). Craniopharyngioma: suprasellar, presents with visual field deficits (bitemporal hemianopia), endocrine deficits (growth hormone deficiency, diabetes insipidus, precocious or delayed puberty), and hydrocephalus. Hypotonia: central (CP, genetic syndromes, metabolic, hypothyroidism) vs peripheral (SMA, congenital muscular dystrophy, myasthenia, myotonic dystrophy, congenital myopathy). Spinal muscular atrophy (SMA): SMN1 deletion, floppy infant, areflexia, fasciculations of the tongue, normal intelligence, and progressive weakness; diagnosis: genetic testing. Treatment: nusinersen (Spinraza, intrathecal), onasemnogene abeparvovec (Zolgensma, gene therapy), and risdiplam (Evrysdi, oral). Newborn screening for SMA is now universal in the US.

Iron deficiency anemia (IDA) is the most common hematologic disorder in children, with peak prevalence at 9–24 months. Etiologies include inadequate dietary iron (prolonged exclusive breastfeeding without iron-rich complementary foods, excessive cow milk intake >24 oz/day, vegetarian/vegan diet, prolonged bottle-feeding), iron malabsorption (celiac disease, IBD, autoimmune atrophic gastritis, H. pylori gastritis, post-gastrectomy), blood loss (Meckel diverticulum, GI polyp, IBD, NSAID use, parasitic infection, menstruation in adolescent girls), and increased iron requirements (rapid growth in infancy and adolescence). CBC shows microcytic (low MCV), hypochromic (low MCHC) anemia with an elevated red cell distribution width (RDW >15%), indicating heterogeneous cell size (anisocytosis). Serum ferritin is the most sensitive test for iron stores; low ferritin (<12–15 ng/mL) confirms IDA. However, ferritin is an acute-phase reactant and may be falsely elevated in inflammatory states. Serum iron is low, TIBC is elevated, and transferrin saturation is low (<16%). The Mentzer index (MCV/RBC count) helps distinguish IDA from thalassemia trait: >13 suggests IDA, <13 suggests thalassemia trait. The RDW is elevated in IDA (anisopoikilocytosis) but normal in thalassemia trait. Peripheral smear in IDA shows pencil-shaped (elliptical) cells, anisopoikilocytosis, and target cells (few). In thalassemia, target cells are prominent with minimal anisocytosis. Lead poisoning can also cause microcytic anemia with basophilic stippling on smear; check lead levels in at-risk children (all Medicaid children at 12 and 24 months, universal screening in high-prevalence areas). Treatment of IDA: oral ferrous sulfate 3–6 mg/kg/day of elemental iron in 2–3 divided doses, given between meals with vitamin C (ascorbic acid) to enhance absorption. Avoid concurrent administration of milk, tea, coffee, calcium supplements, and antacids. Response: reticulocytosis in 3–7 days, followed by a rise in Hb of 1 g/dL every 2–4 weeks. Continue supplementation for at least 2–3 months after Hb normalizes to replenish iron stores. IV iron is reserved for severe, refractory, or malabsorptive cases. Thalassemia syndromes: alpha-thalassemia is caused by deletion of one or more alpha-globin genes on chromosome 16; severity depends on deletion number (one: silent carrier, two: trait/ mild microcytic anemia, three: HbH disease with moderate hemolytic anemia, four: Bart hydrops fetalis incompatible with life). Beta-thalassemia is caused by point mutations in beta-globin genes on chromosome 11; beta-thalassemia minor/trait shows microcytosis with elevated HbA2 (>3.5%); beta-thalassemia intermedia (moderate anemia, may need occasional transfusions, iron overload risk); beta-thalassemia major (Cooley anemia) is transfusion-dependent, presents at 6–12 months with severe anemia, FTT, skeletal deformities (frontal bossing, maxillary overgrowth, chipmunk facies), hepatosplenomegaly, and iron overload even without transfusion due to ineffective erythropoiesis and increased GI absorption. Management: chronic transfusion program (target pre-transfusion Hb >9–10 g/dL to suppress erythropoiesis), iron chelation (deferasirox PO, deferoxamine SC/IV, deferiprone), and curable with hematopoietic stem cell transplant (HSCT) from matched sibling donor. Hemolytic anemias: hereditary spherocytosis (autosomal dominant, spectrin deficiency, spherical RBCs, increased osmotic fragility, splenomegaly, gallstones, aplastic crisis with parvovirus B19; splenectomy after age 5–6 is curative after appropriate vaccinations), G6PD deficiency (X-linked, oxidative hemolysis with infections, fava beans, sulfa drugs, nitrofurantoin, dapsone, methylene blue; Heinz bodies on smear, bite cells; self-limited hemolysis, supportive care, avoid triggers), autoimmune hemolytic anemia (warm AIHA: IgG, positive direct Coombs, treat with steroids, IVIG, rituximab; cold AIHA: IgM, often post-Mycoplasma or EBV, treat by avoiding cold and addressing underlying infection).

Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy caused by a point mutation (Glu6Val) in the beta-globin gene, resulting in hemoglobin S (HbS). The most common genotypes are HbSS (sickle cell anemia, most severe), HbSC (commonly milder, but increased risk of retinopathy and avascular necrosis), HbS-beta-plus-thalassemia (mild), and HbS-beta-zero-thalassemia (similar to HbSS). Newborn screening identifies all infants; penicillin prophylaxis 125 mg BID beginning at 2 months for HbSS/HbS-beta-zero-thal, increased to 250 mg BID at 3 years, continued through age 5. Pneumococcal, meningococcal, and influenza vaccinations are critical. Disease-modifying therapy: hydroxyurea (HU) is first-line for HbSS and HbS-beta-zero-thal starting at 9–12 months of age, targeting a neutrophil count >2000 and HbF >20%. HU reduces vaso-occlusive crises (VOC) by 50%, reduces acute chest syndrome (ACS), improves Hb, reduces transfusions, and decreases mortality. L-glutamine (Endari) is an oral antioxidant that reduces VOC by 25%. Crizanlizumab (Adakveo) is an IV anti-P-selectin monoclonal antibody that reduces VOC frequency by 45%. Voxelotor (Oxbryta) is an oral HbS polymerization inhibitor that increases Hb by 1 g/dL and reduces hemolysis, but does not reduce VOC. Hematopoietic stem cell transplant (HSCT) from a matched sibling donor is curative but limited to <20% of patients (5-year event-free survival >85%). Gene therapy (lovo-cel, exagamglogene autotemcel Casgevy) is now available. Acute complications: VOC (most common, treat with IV hydration, NSAIDs, and opioids; incentive spirometry to prevent ACS), acute chest syndrome (new pulmonary infiltrate + fever/respiratory symptoms, leading cause of death; treat with ceftriaxone + azithromycin, bronchodilators, simple or exchange transfusion), stroke (overt or silent cerebral infarcts; TCD screening annually starting at 2–16 years; abnormal TCD >200 cm/s → chronic transfusion to keep HbS <30%), splenic sequestration (rapid splenic enlargement + Hb drop ≥2 g/dL; treat with transfusion; splenectomy if recurrent), aplastic crisis (parvovirus B19, reticulocytopenia; supports with transfusion; self-limited), priapism (>4 hours → urologic emergency, exchange transfusion, aspiration/irrigation), and bilious gallstones.

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, accounting for 25–30% of pediatric malignancies, with peak incidence at 2–5 years. Presenting signs: fever (from neutropenia or leukemia itself), pallor (anemia), bruising/petechiae/bleeding (thrombocytopenia), bone pain (especially long bones, limp, refusal to bear weight), hepatosplenomegaly, lymphadenopathy, and less commonly CNS involvement (headache, vomiting, CN palsy). Labs: pancytopenia, leukocytosis (but can be normal or leukopenic), blasts on peripheral smear, LDH elevated, uric acid elevated. Diagnosis: bone marrow aspirate and biopsy with ≥25% lymphoblasts, flow cytometry (B-ALL: CD19+, CD10+/CALLA, CD20+, CD22, CD79a, PAX5; T-ALL: CD3+, CD7+, CD1a, CD4/CD8), and cytogenetics/molecular testing. Risk stratification (NCI/Rome): standard risk (age 1–9.9yr, WBC <50K) vs high risk (≥10yr or WBC ≥50K). Cytogenetic risk: good (ETV6-RUNX1, hyperdiploidy >50), poor (BCR-ABL1 Philadelphia chromosome, KMT2A rearrangements, hypodiploidy, iAMP21). Treatment: multi-agent chemotherapy for 2–3 years divided into induction (vincristine + dexamethasone/prednisone + PEG-asparaginase +/- anthracycline), consolidation, interim maintenance, delayed intensification, and maintenance (oral methotrexate + 6-mercaptopurine). CNS prophylaxis: intrathecal methotrexate. Survival exceeds 85% in children, with >90% for standard-risk B-ALL. CNS-directed radiotherapy is reserved for high-risk patients with CNS leukemia at diagnosis. Relapse occurs in 15–20%, most commonly in bone marrow; treated with reinduction chemotherapy and HSCT. Wilms tumor (nephroblastoma) is the most common renal tumor in children, peak 3–4 years, presenting with an asymptomatic flank or abdominal mass (often found by parent while bathing or during well-child exam). Hematuria (20%), hypertension (25%), and associated syndromes: WAGR (Wilms, aniridia, GU anomalies, intellectual disability: WT1 deletion on 11p13), Beckwith-Wiedemann syndrome (hemihypertrophy, macroglossia, omphalocele, predisposition to Wilms and hepatoblastoma; 11p15 overgrowth), Denys-Drash syndrome (nephropathy, GU anomalies, Wilms: WT1 point mutation). Ultrasound/CT: intrarenal mass. Chest CT: lung metastases (most common metastatic site). COG staging: I (limited to kidney, completely excised, intact capsule), II (extends beyond kidney but completely excised), III (residual tumor, lymph node involvement, or capsular rupture/spillage), IV (hematogenous metastases), V (bilateral at diagnosis). Favorable histology (FH, 90%) has excellent prognosis; anaplastic histology (unfavorable, 10%) requires more intensive therapy. Treatment: radical nephrectomy + chemotherapy (vincristine + actinomycin D for stage I–II FH; add doxorubicin for stage III–IV FH) + radiation therapy (for stage III/IV or anaplastic). Stage V (bilateral): neoadjuvant chemotherapy, attempt partial nephrectomy. Overall survival: 90% for favorable histology. Neuroblastoma is the most common extracranial solid tumor in children, peak 18–24 months, arising from neural crest cells of the sympathetic nervous system. The most common primary site is the adrenal medulla (40%), followed by abdominal sympathetic chain, chest, and neck. Presentation: abdominal mass that crosses midline (firm, irregular, tender), proptosis and periorbital ecchymosis (raccoon eyes from periorbital metastases), bone pain/limp/irritability (bone metastases), Horner syndrome (ptosis, miosis, anhidrosis from apical chest primary), opsoclonus-myoclonus-ataxia syndrome (paraneoplastic: dancing eyes, dancing feet, ataxia, associated with good prognosis), fever, weight loss, hypertension (catecholamine excess), and bluish subcutaneous nodules (blueberry muffin baby) in stage 4S (<12mo). Diagnosis: elevated urine catecholamines VMA/HVA in >90%; imaging (US, CT/MRI for local staging); MIBG scan highly sensitive and specific for staging; bone marrow biopsy. Risk stratification (COG): age <18mo favorable, MYCN amplification (strongest adverse prognostic factor), INSS stage (1–4, 4S), histology (favorable vs unfavorable), DNA index (hyperdiploidy favorable), and segmental chromosome aberrations (1p, 11q, 17q). Treatment: low-risk → surgery alone (many regress spontaneously, especially stage 4S). Intermediate-risk → surgery + chemotherapy (carboplatin, etoposide, cyclophosphamide, doxorubicin) +/- radiation. High-risk → induction chemotherapy, surgery, myeloablative chemotherapy with autologous stem cell rescue (ASCR), radiation, and post-consolidation with cis-retinoic acid (isotretinoin) + anti-GD2 immunotherapy (dinutuximab with GM-CSF, IL-2). Survival: low-risk >95%, high-risk 50–60%. Hodgkin lymphoma: bimodal distribution (adolescents and older adults), painless firm cervical/supraclavicular lymphadenopathy, mediastinal mass (often incidental on CXR), and B symptoms (fever >38C, night sweats, weight loss >10%). Reed-Sternberg cells (CD15+, CD30+) on excisional biopsy. Staging: PET-CT, CT chest/abdomen/pelvis. Treatment: ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) +/- radiation. Survival >90%. Non-Hodgkin lymphoma in children: Burkitt (c-myc translocation, abdominal mass, jaw involvement, high-grade, intensive chemotherapy), lymphoblastic (T-cell, mediastinal mass, SVCS, ALL-type chemotherapy), and DLBCL.

Hemophilia A (factor VIII deficiency, X-linked, 1/5000 males) and hemophilia B (factor IX deficiency, X-linked, 1/30,000 males) present with deep joint bleeds (hemarthroses: knees, elbows, ankles), deep muscle hematomas, easy bruising, prolonged bleeding after dental procedures/surgery/trauma, and life-threatening intracranial hemorrhage (ICH). Severity: severe (<1% FVIII/FIX activity, spontaneous bleeds, >10 joint bleeds/year without prophylaxis), moderate (1–5%, bleeding after minor trauma, some spontaneous), mild (6–40%, bleeding after surgery or major trauma). Diagnosis: prolonged aPTT (normal PT, BT, platelet count). FVIII activity, FIX activity, and von Willebrand panel (VWF Ag, ristocetin cofactor, FVIII-level) to differentiate from VWD. In hemophilia A, pre-treatment with DDAVP 0.3 mcg/kg IV/SC (releases endogenous FVIII) can be effective for mild bleeds. Management of acute bleeding: IV factor replacement. For hemophilia A: recombinant or plasma-derived FVIII, 25–50 IU/kg for mild bleeds, 50–100 IU/kg for major bleeds/ICH, then q12h. For hemophilia B: FIX concentrate 50–100 IU/kg for major bleeds, then q24h (FIX has longer half-life). Adjunctive: tranexamic acid 25 mg/kg PO/IV for mucosal bleeds. Prophylaxis: routine replacement FVIII 25–40 IU/kg 3x/week or FIX 25–60 IU/kg 2x/week, started at age 1–2 years after first joint bleed, to prevent arthropathy. Emicizumab (Hemlibra) is a bispecific humanized monoclonal antibody that bridges FIXa and FX, mimicking FVIII function; given SC weekly/biweekly/monthly for hemophilia A with or without inhibitors, highly effective (TGN1412-like molecule, not a clotting factor). Inhibitors (neutralizing alloantibodies) develop in 20–30% of severe hemophilia A patients; management: ITI (immune tolerance induction with daily FVIII infusions 100 IU/kg), bypassing agents (rFVIIa, aPCC), or emicizumab. Immune thrombocytopenia (ITP) is an acquired autoimmune condition with isolated thrombocytopenia (<100,000/uL, often <20,000/uL) in a well-appearing child, typically 1–4 weeks after viral infection or immunization, peak age 2–5 years. Petechiae, purpura, easy bruising, epistaxis, and oral mucosal bleeds are common; intracranial hemorrhage (ICH) is rare (<0.5–1%). Diagnosis: clinical history and CBC showing isolated thrombocytopenia without other hematologic abnormalities. Peripheral smear shows normal WBC and RBC morphology with decreased platelets, some may be large. Bone marrow aspirate is NOT needed unless atypical features (systemic symptoms, hepatosplenomegaly, abnormal WBC/RBC on smear, persistent or refractory course). Acute ITP (duration <6 months) resolves spontaneously in >80% of children within 3–6 months. Persistent (3–12 months) and chronic (>12 months) ITP also have high spontaneous remission rates. Treatment guidelines: observation is appropriate if no bleeding or mild skin bleeding only (wet purpura, epistaxis <20 min, no mucosal or internal bleeding). First-line therapy for clinically significant bleeding: IVIG 1 g/kg over 8–12 hours (raises platelets within 24–48 hours) or anti-D (50–75 mcg/kg IV, Rh-positive only, non-splenectomized, risk of severe hemolysis and DIC) or prednisone 2–4 mg/kg/day PO for 2–4 weeks with taper. Second-line: romiplostim (TPO-agonist, weekly SC), eltrombopag (oral TPO-agonist), rituximab (anti-CD20), or splenectomy (deferred as much as possible due to risk of overwhelming post-splenectomy infection OPSI, need for vaccinations before surgery). Avoid contact sports, NSAIDs, and aspirin while platelets are <30,000–50,000.

Febrile neutropenia (FN) is a medical emergency defined as a single oral temperature ≥38.3C (101F) or sustained temperature ≥38.0C (100.4F) for >1 hour in a patient with an absolute neutrophil count (ANC) <500 cells/uL (or expected to fall below 500 within 48 hours). It is a common complication of intensive chemotherapy due to bone marrow suppression. Pathogens: gram-positive (coagulase-negative staph, S. aureus, viridans group strep, Enterococcus, including VRE) are most common, followed by gram-negative (E. coli, Klebsiella, Pseudomonas aeruginosa), and fungal (Candida, Aspergillus) in prolonged neutropenia (>7–10 days). Initial evaluation: complete history and physical (including oral cavity, skin, perianal area, and central line sites); blood cultures from each lumen of the central line and a peripheral vein; CBC with differential, CMP, CRP; and CXR if respiratory symptoms. Empiric broad-spectrum IV antibiotics must be started within 1 hour of presentation: monotherapy with an antipseudomonal beta-lactam (cefepime, meropenem, piperacillin-tazobactam) is preferred. Vancomycin should be added if there is suspicion for MRSA (severe mucositis, skin/soft tissue infection, hemodynamic instability, known MRSA colonization, or suspected tunneled catheter infection). Modifications based on cultures, clinical response, and duration of neutropenia. Persistent fever despite antibiotics: consider adding an antifungal (voriconazole for Aspergillus, echinocandin for Candida). G-CSF (filgrastim) is not routinely recommended for FN but may be used for secondary prophylaxis. Monitoring: daily blood counts, blood cultures if recrudescent fever, and to monitor for complications. Tumor lysis syndrome (TLS) is a metabolic emergency caused by rapid destruction of tumor cells releasing intracellular contents (uric acid, potassium, phosphate, calcium) into the bloodstream, most commonly occurring during induction chemotherapy for high-grade lymphomas (Burkitt) or acute leukemias with high tumor burden. Labs: hyperuricemia (uric acid >8 mg/dL), hyperkalemia (>6.0 mEq/L, risk of cardiac arrhythmias), hyperphosphatemia (>6.5 mg/dL), and hypocalcemia (due to calcium-phosphate precipitation). Cairo-Bishop classification: laboratory TLS (2 or more metabolic abnormalities within 3 days before to 7 days after chemotherapy) vs clinical TLS (laboratory TLS plus ≥1 clinical complication: elevated Cr ≥1.5x ULN, cardiac arrhythmia/sudden death, seizure). Prevention: aggressive IV hydration (normal saline 200–300 mL/m2/day), allopurinol (prevents new uric acid formation, 300 mg/m2/day PO, for low-risk) or rasburicase (recombinant urate oxidase, rapidly breaks down existing uric acid, 0.15–0.2 mg/kg IV, for high-risk), and monitoring of serum electrolytes (K, Ca, PO4) Q6–12h. Management of clinical TLS: aggressive IV hydration, rasburicase (for hyperuricemia), calcium gluconate (for symptomatic hypocalcemia or hyperkalemia with ECG changes), insulin/glucose/bicarbonate/albuterol (for hyperkalemia), and renal replacement therapy (hemodialysis) if severe hyperuricemia unresponsive to rasburicase, severe hyperkalemia, or progressive AKI.

Type 1 diabetes (T1D) is an autoimmune disease characterized by T-cell mediated destruction of pancreatic beta cells, leading to absolute insulin deficiency. The peak incidence is at 10–14 years, but it can present at any age, including infancy. Genetic susceptibility is conferred by HLA-DR3/DR4-DQ8 haplotypes, while environmental triggers (enteroviral infections, early cow milk exposure, vitamin D insufficiency) may initiate or accelerate the autoimmune process. Islet cell autoantibodies (GAD-65, IA-2, insulin autoantibody IAA, and zinc transporter ZnT8) appear months to years before clinical onset. Classic presentation: polyuria (nocturnal enuresis in a previously toilet-trained child), polydipsia, polyphagia, weight loss, fatigue, blurred vision, and recurrent infections. Diabetic ketoacidosis (DKA) is the presenting feature in 30–40% of new-onset T1D in children, and results from absolute insulin deficiency causing uncontrolled lipolysis, ketogenesis, and metabolic acidosis. DKA diagnosis: hyperglycemia (glucose >200 mg/dL >11 mmol/L), venous pH <7.3 or HCO3 <15 mmol/L, and ketonemia/ketonuria (beta-hydroxybutyrate ≥3 mmol/L). Severity: mild (pH 7.2–7.3, HCO3 10–15), moderate (pH 7.1–7.2, HCO3 5–10), severe (pH <7.1, HCO3 <5). DKA management (SPC/ISPAD guidelines): (1) IV fluid resuscitation (normal saline 10–20 mL/kg over 30–60 min, max 40 mL/kg in first 4 hours; deficit replacement with 0.45% NaCl over 36–48 hours). (2) Insulin therapy: start IV regular insulin 0.05–0.1 units/kg/hour at least 1 hour after starting fluids (to avoid rapid fluid shifts and cerebral edema). (3) Potassium replacement: add K+ to fluids once K+ <5.5 and patient is voiding (40 mEq/L). (4) Glucose monitoring: when blood glucose drops to 250–300 mg/dL, add dextrose (5–10%) to IV fluids. (5) Bicarbonate: NOT recommended unless pH <6.9 with severe cardiovascular instability (cardiac depression). (6) Monitor for cerebral edema (the leading cause of DKA mortality): headache, vomiting, irritability, confusion, bradycardia, hypertension. Risk factors for cerebral edema: age <5 years, new-onset T1D, severe acidosis (pH <7.1), high BUN, and rapid correction of hyperosmolality with excessive IV fluids or bicarbonate. Treatment of cerebral edema: immediately reduce IV fluids, head elevation, IV mannitol 0.5–1 g/kg or hypertonic saline (3%) 2.5–5 mL/kg over 15 min. Long-term management of T1D: basal-bolus insulin regimen via multiple daily injections (MDI: long-acting glargine/detemir/degludec + rapid-acting lispart/aspart/glulisine) or continuous subcutaneous insulin infusion (CSII, insulin pump). Continuous glucose monitoring (CGM: Dexcom G7, Freestyle Libre 3, Guardian 4) has become standard of care. The goal is to keep HbA1c <7% (ISPAD) while minimizing hypoglycemia. Time-in-range (TIR, 70–180 mg/dL) should be >70%. Automated insulin delivery (AID) systems (hybrid closed-loop, e.g., Medtronic 780G, Tandem Control-IQ, Omnipod 5, CamAPS FX) combine CGM + insulin pump + algorithm to adjust basal insulin automatically and provide correction boluses, dramatically improving TIR and reducing hypoglycemia burden. Honeymoon phase (partial remission): transient residual beta-cell function in the first 3–12 months after diagnosis, during which insulin requirements may be very low (<0.5 U/kg/day) and glycemic control is excellent. This is an important window for preserving beta-cell function through immunomodulatory therapy (teplizumab, anti-CD3, now FDA-approved to delay onset of T1D in at-risk individuals). Thyroid autoimmunity (Hashimoto thyroiditis) is common in T1D (up to 30%); screen TSH annually.

Short stature is defined as height <3rd percentile (or <-2 SD) for age and sex. The evaluation begins with accurate height measurement using a calibrated stadiometer, calculation of mid-parental target height (MPH: for boys = [fathers height + mothers height + 13]/2; for girls = [fathers height + mothers height - 13]/2; normal range ±8.5 cm), and assessment of growth velocity over 6–12 months. Physiologic variants: familial short stature (FSS, height appropriate for MPH, normal growth velocity, normal bone age = chronologic age), constitutional delay of growth and puberty (CDGP, delayed bone age, delayed puberty, normal growth velocity for bone age, family history of late bloomers, ultimately achieve normal adult height). Pathologic short stature: growth hormone deficiency (GHD, slow growth velocity <5 cm/year after age 4, delayed bone age, history of perinatal insult: breech delivery, hypoglycemia, jaundice, microphallus in boys), Turner syndrome (gonadal dysgenesis, webbed neck, low hairline, broad chest, wide-spaced nipples, increased carrying angle, coarctation, lymphedema at birth; karyotype 45,X), Noonan syndrome (short stature, webbed neck, pectus carinatum/excavatum, pulmonary stenosis, hypertrophic cardiomyopathy, low-set ears, ptosis, hypertelorism, downslanting palpebral fissures), small for gestational age (SGA) without catch-up growth, chronic systemic disease (celiac, IBD, CKD, CF, JIA, hypothyroidism), and skeletal dysplasias (achondroplasia, SHOX deficiency: disproportionate short stature with Madelung deformity of wrist). Labs: bone age (left hand XR, compared to Greulich-Pyle atlas; delayed in GHD/CDGP/hypothyroidism, advanced in precocious puberty/obesity). Screening: IGF-1 and IGFBP-3 (low in GHD, but can be normal in mild deficiency or malnutrition). Two pharmacologic growth hormone stimulation tests (using clonidine, arginine, glucagon, or insulin-induced hypoglycemia) are needed to confirm GHD if IGF-1 is low and growth velocity is poor. A peak GH <7–10 ng/mL confirms GHD. MRI brain with pituitary protocol (thin cuts through sella) is indicated to evaluate for pituitary stalk interruption syndrome, septo-optic dysplasia, CNS tumors (craniopharyngioma, germinoma), and empty sella. Karyotype (Turner in all girls with unexplained short stature) and microarray/SNP array (for SHOX deficiency). Treatment: recombinant human GH (rhGH, somatropin, 0.025–0.05 mg/kg/day SC) for GHD, Turner syndrome, SGA without catch-up, SHOX deficiency, Noonan syndrome, and CKD-associated growth failure. GH therapy is highly effective in GHD (gains of 8–12 cm in first year). Monitoring: height, weight, IGF-1, bone age, and screening for adverse effects (pseudotumor cerebri, slipped capital femoral epiphysis, glucose intolerance, scoliosis progression, increased risk of neoplasia). GH should not be used in active malignancy or critical illness. GH therapy is typically continued until final height (bone age ≥16 in boys, ≥14 in girls) or achievement of satisfactory adult height.

Congenital hypothyroidism (CH) occurs in 1 in 2000–4000 newborns and is the most common preventable cause of intellectual disability. Newborn screening (elevated TSH on blood spot) identifies CH before symptoms develop. Causes: thyroid dysgenesis (aplasia, hypoplasia, ectopia, 80–85%) or dyshormonogenesis (defect in thyroid hormone synthesis, 10–15%); transient CH (maternal TSH receptor-blocking antibodies, iodine deficiency/excess, maternal antithyroid medications). Clinical features (in unscreened infants): prolonged jaundice, large fontanelles, coarse facies, macroglossia, hoarse cry, umbilical hernia, hypotonia, constipation, poor feeding, lethargy, and developmental delay (prevented by early treatment). Treatment: levothyroxine 10–15 mcg/kg/day PO (crushed tablet, NOT suspension), started immediately after confirmatory serum TSH and free T4. Goal: normalize free T4 within 2 weeks and TSH within 1 month. Monitor TSH and free T4 q1–2 months in the first year, then every 3–4 months thereafter. Graces disease in children presents with hyperthyroidism (weight loss, heat intolerance, tachycardia, tremor, exophthalmos, lid lag, goiter), behavioral changes (irritability, poor school performance), and accelerated growth/bone age. Diagnosis: suppressed TSH, elevated free T4/T3, positive TSI (thyroid-stimulating immunoglobulin). Treatment: first-line is methimazole (0.5–1 mg/kg/day divided q12h). Propylthiouracil (PTU) is reserved for the first trimester of pregnancy, pre-thyroidectomy preparation, and thyroid storm due to hepatotoxicity risk. Adjunctive: beta-blockers (propranolol 1–2 mg/kg/day) for symptomatic tachycardia. Definitive therapy: radioactive iodine (RAI-131) or total thyroidectomy. RAI is generally avoided in prepubertal children due to theoretical risk of secondary malignancy and is contraindicated in Graves ophthalmopathy. Thyroidectomy is preferred for large goiters, moderate-severe eye disease, MTC (MEN2), or patient choice. Congenital adrenal hyperplasia (CAH): 21-hydroxylase deficiency accounts for >95% of CAH cases. It impairs cortisol and aldosterone synthesis, leading to ACTH-driven accumulation of precursor 17-hydroxyprogesterone (17-OHP) and androgen excess. Classic CAH: salt-wasting (SW, 75%, with aldosterone deficiency: hyponatremia, hyperkalemia, hypovolemia, shock in the first 2–4 weeks of life) vs simple virilizing (SV, 25%, without salt wasting). Females with classic CAH present at birth with ambiguous genitalia (clitoral enlargement, labial fusion, urogenital sinus). Males with SW present with failure to thrive, vomiting, lethargy, hyponatremia, hyperkalemia, and shock (adrenal crisis). Newborn screening (elevated 17-OHP on blood spot) identifies cases. Diagnosis: elevated 17-OHP, elevated renin (in SW), karyotype for sex assignment in ambiguous genitalia, and ACTH stimulation test for confirmation. Treatment: hydrocortisone (15–25 mg/m2/day divided TID, higher stress doses for illness, surgery, trauma) and fludrocortisone (0.1–0.2 mg/day) for SW forms with salt supplementation (1–3 g/day NaCl in infancy). Monitoring: 17-OHP, androstenedione, renin (for mineralocorticoid adequacy), and growth/bone age (to avoid overtreatment with glucocorticoids). Stress dosing (e.g., triple or quadruple daily dose) during febrile illness, injury, or surgery prevents adrenal crisis. Adrenal crisis management: IV NS bolus 20 mL/kg, IV hydrocortisone 100 mg/m2 bolus, then 100–200 mg/m2/day divided q4–6h, dextrose if hypoglycemia.

Central precocious puberty (CPP) is defined by GnRH-dependent activation of the hypothalamic-pituitary-gonadal (HPG) axis, occurring before age 8 in girls or age 9 in boys. Peripheral precocious puberty (PPP) is GnRH-independent, caused by sex steroid secretion from the gonads, adrenal glands, or exogenous sources. In girls, thelarche before age 8 is the most common presentation; menarche before age 10 is also precocious. In boys, testicular enlargement (≥4 mL) before age 9 is the first sign. Rapid progression (advancing >1 Tanner stage in 3–6 months) or accelerated growth velocity warrants evaluation. Etiology of CPP: in girls, 80–90% are idiopathic; in boys, >50% have an underlying CNS lesion (hypothalamic hamartoma, optic glioma, hydrocephalus, history of CNS radiation, encephalitis, trauma). Evaluation: bone age (advanced >2 SD above chronologic age), GnRH stimulation test (peak LH >5 IU/L indicates CPP, LH/FSH ratio >0.66), MRI brain with pituitary protocol (mandatory in all boys and in girls with onset before 6 years), sex steroid levels (estradiol in girls, testosterone in boys). Treatment of CPP: GnRH agonist (leuprolide depot 11.25–30 mg IM q4w–q12w, or histrelin implant 50 mg SC annually) to suppress the HPG axis, preserve adult height potential by slowing skeletal maturation, and halt secondary sexual characteristics. Side effects: transient menstrual bleeding after first dose, hot flashes, mood changes. Monitor suppression of puberty (LH <1 IU/L on GnRH stim, sex steroids in prepubertal range, growth velocity normalized). Delayed puberty is defined as no Tanner B2 by age 13 in girls (or no menarche by 15–16) and no testicular enlargement ≥4 mL by age 14 in boys. Etiology: constitutional delay (CDGP, most common, 60–70%), functional hypogonadotropic hypogonadism (chronic illness, celiac, IBD, hypothyroidism, anorexia/excessive exercise, hyperprolactinemia), permanent hypogonadotropic hypogonadism (Kallmann syndrome with anosmia, congenital hypopituitarism, brain tumors, post-chemotherapy/radiation), and hypergonadotropic hypogonadism (Turner in girls, Klinefelter in boys, galactosemia, chemotherapy/radiation-induced ovarian or testicular failure). Evaluation: bone age (delayed), LH/FSH, sex steroids (low for age, low in hypogonadotropic, high in hypergonadotropic), prolactin, TSH, free T4, IGF-1, karyotype (Turner/Klinefelter), MRI brain (if LH/FSH low or anosmia), smell test. Treatment: observation with monitoring every 3–6 months for CDGP. Induction of puberty in hypogonadotropic hypogonadism: estradiol (girls, starting low dose 0.25–0.5 mg/day PO or 0.1 mg patch, titrate up every 6–12 months) or testosterone (boys, starting 50 mg IM monthly of testosterone cypionate/enanthate, titrate gradually over 2–3 years). For hypergonadotropic hypogonadism, hormone replacement therapy as above but at physiologic doses.

Ambiguous genitalia (disorder of sex development, DSD) is a medical and psychosocial emergency requiring a multidisciplinary team (endocrinology, genetics, urology, psychology, neonatology). Presentation: a newborn with any of — clitoral enlargement (>1 cm), labial fusion, palpable gonads in the labia, non-palpable testes, bilaterally undescended testes, isolated perineal hypospadias with bifid scrotum, or apparent male with bilateral undescended testes or micropenis. Initial evaluation: physical exam (palpable gonads suggest male DSD, absent suggest female DSD), karyotype/ FISH for SRY, serum electrolytes (hyponatremia/hyperkalemia suggests salt-wasting CAH), 17-OHP (elevated in 21-hydroxylase CAH), testosterone, DHT, LH, FSH, AMH, renin, aldosterone, and abdominal/pelvic ultrasound for Mullerian structures. The most common cause of ambiguous genitalia in a 46,XX infant is congenital adrenal hyperplasia (21-hydroxylase deficiency). In a 46,XY infant, causes include androgen insensitivity syndrome (AIS, complete: female external genitalia, absent uterus, testes present, normal testosterone, elevated LH), 5-alpha-reductase deficiency (46,XY with undervirilization at birth, virilization at puberty, testosterone/DHT ratio >10), and gonadal dysgenesis (partial or mixed). Gender assignment is deferred until evaluation is complete, with the goal of assigning gender that aligns with likely adult gender identity, fertility potential, and surgical feasibility. Neonatal hypoglycemia workup: when hypoglycemia persists beyond the first 2–3 days of life or requires >10–12 mg/kg/min glucose, the critical sample (blood drawn at the time of hypoglycemia) is essential: glucose, insulin, C-peptide, cortisol, GH, beta-hydroxybutyrate, free fatty acids, lactate, ammonia, amino acids, and urine organic acids. This differentiates hyperinsulinism (low ketones, low FFA, elevated insulin/C-peptide, glycemic response to glucagon) from other causes (hypopituitarism, GHD, cortisol deficiency, fatty acid oxidation disorders, glycogen storage diseases, ketotic hypoglycemia). Transient hyperinsulinism is common in infants of diabetic mothers, SGA/LGA, and those with perinatal stress. Persistent hyperinsulinism (if GIR >10–12 mg/kg/min) requires diazoxide (5–15 mg/kg/day) plus chlorothiazide (to prevent fluid retention). Octreotide or continuous glucagon may be used as bridge therapies. Type 2 diabetes in adolescents has increased dramatically with the rise in childhood obesity. Diagnosis: ADA criteria (HbA1c ≥6.5%, FBG ≥126, 2h OGTT ≥200, or random ≥200 with symptoms). Distinguishing T2 from T1D in obese adolescents can be challenging: T2D typically presents with acanthosis nigricans, obesity, positive family history of T2D, and absence of islet autoantibodies (negative GAD, IA-2, ZnT8) and preserved C-peptide. Treatment: metformin (first-line, 500 mg BID up to 2000 mg/day) + lifestyle modifications (diet, exercise). Liraglutide (GLP-1 RA) is FDA-approved for adolescents ≥10 years. Insulin therapy is indicated if severe hyperglycemia (HbA1c >9–10%, glucose >250), ketosis, or symptomatic with weight loss. Orlistat (weight loss) is an option. Metformin + lifestyle is often insufficient long-term due to progressive beta-cell decline; early consideration of additional glucose-lowering agents is warranted.

Down syndrome is the most common chromosomal disorder, occurring in approximately 1 in 700–800 live births. The incidence increases with maternal age: 1 in 1500 at age 20, 1 in 350 at age 35, and 1 in 35 at age 45. Most cases (95%) result from nondisjunction during maternal meiosis I, 3–4% from Robertsonian translocation (most commonly between chromosomes 14 and 21; carrier parent, especially if <30 years, has a 10–15% recurrence risk if maternal carrier, 2–5% if paternal), and 1% from mosaicism (variable phenotype depending on the proportion of trisomic cells). Characteristic features: craniofacial — brachycephaly (short, broad head), flat facial profile, epicanthal folds, upslanting palpebral fissures, Brushfield spots (iris), small ears with overfolded helix, small nose with flat nasal bridge, protruding tongue (macroglossia relative to small oral cavity), and open mouth. Extremities: single transverse palmar crease (simian crease, 45%), clinodactyly (incurved 5th finger), sandal gap (wide space between 1st and 2nd toes), and hyperflexibility. Associated medical conditions (by frequency): congenital heart disease (40–50%, most commonly AVSD [atrioventricular septal defect, 40–50% of CHD in DS, vs 3% of CHD in the general population], VSD, ASD, PDA), gastrointestinal (duodenal atresia/stenosis, Hirschsprung disease, imperforate anus, celiac disease ≥5%), hearing loss (50–70%, conductive from chronic serous otitis media and sensorineural), vision problems (60%: cataracts, glaucoma, refractive errors, strabismus, nystagmus), hypothyroidism (15–20%, congenital and acquired, screen TSH annually), cervical spine instability (15–20% with atlantoaxial instability, <2% symptomatic; pre-participation sports screening with flexion-extension cervical spine XR at age 3–5 years), obstructive sleep apnea (50–80% from midface hypoplasia, macroglossia, hypotonia), leukemia (ALL and AML, 15–20 times increased risk, especially transient myeloproliferative disorder in newborns with GATA1 mutations; 20–30% of TMD resolves spontaneously but 20–30% of those develop AMKL by age 4), intellectual disability (mild-moderate, IQ 40–70, with relative strength in visual-spatial skills but weakness in language and executive function), Alzheimer disease (virtually all individuals over age 40 have neuropathologic changes of Alzheimers due to the extra APP gene on chromosome 21; clinical dementia develops in 50–70% by age 60–70). Screening and diagnosis: prenatal screening (NIPT/cell-free DNA highly sensitive for trisomy 21, first-trimester combined screen [PAPP-A + hCG + nuchal translucency] or quad screen [AFP, hCG, uE3, inhibin A in second trimester]), then diagnostic testing (CVS or amniocentesis). Postnatal diagnosis: karyotype or FISH confirms. Medical monitoring: echocardiogram at birth, hearing and vision screening, TSH/free T4 annually, celiac serology at age 2–3 years (or if symptomatic), cervical spine XR before activities that risk neck hyperextension (Special Olympics, tumbling, contact sports). There is no cure for DS; supportive and medical management with a multidisciplinary approach (developmental pediatrics, cardiology, audiology, ophthalmology, endocrinology, gastroenterology, genetics, PT/OT/ST) optimizes outcomes. Life expectancy for individuals with DS has increased dramatically from 25 years in the 1980s to 60 years today.

Turner syndrome (TS) affects approximately 1 in 2000–2500 live-born females, caused by complete or partial loss of the second X chromosome (most commonly 45,X). Mosaicism (45,X/46,XX or 45,X/46,XY) is present in 30–40% and may result in milder or variant phenotypes. Key clinical features at diagnosis vary by age: prenatal — increased nuchal translucency, cystic hygroma, hydrops, left-sided CHD; infancy — congenital lymphedema of hands and feet, low posterior hairline, webbed neck (pterygium colli), broad chest with widely spaced nipples (shield chest), and coarctation of the aorta; childhood — short stature (presenting as unexplained growth failure in early childhood, height usually <3rd percentile, with an adult height deficit of about 20 cm without GH therapy), gonadal dysgenesis (streak gonads, primary amenorrhea in adolescence, delayed puberty, lack of breast development, infertility), cubitus valgus (increased carrying angle), high-arched palate, multiple nevi, hypoplastic/ hyperconvex nails, and a tendency toward conductive hearing loss and chronic otitis media; adolescence — delayed puberty, short stature, and webbed neck. Medical comorbidities: CHD (30–50%: bicuspid aortic valve [15–30%], coarctation of the aorta [7–15%], partial anomalous pulmonary venous return, dilated ascending aorta with risk of aortic dissection/rupture, especially in the third or fourth decade), sensorineural/conductive hearing loss (50–90% require hearing aids by adulthood), hypothyroidism (15–30%, autoimmune Hashimoto thyroiditis), celiac disease (5–10%), type 2 diabetes (increased), osteoporosis (from estrogen deficiency), and renal anomalies (horseshoe kidney, duplicated collecting system, 30–40%). Cognitive profile: normal intelligence, but specific learning disabilities (nonverbal learning disorder: difficulty with spatial reasoning, visuospatial deficits, math calculation, social cognition, and executive functioning; strength in verbal skills). Diagnosis: karyotype (45,X or mosaic). Management: GH therapy (rhGH 0.05 mg/kg/day SC, approved by FDA for TS, improves adult height by 5–8 cm when started early; should be started as soon as growth failure is detected, often at age 4–6 years). Estrogen replacement: induction of puberty with transdermal estradiol (starting at age 11–12 years, low dose, titrate up over 2–3 years) followed by cyclic estrogen-progestin therapy for maintenance. Monitoring: echocardiogram at diagnosis and q1–5 years (aortic root diameter), blood pressure monitoring, TSH/free T4 annually, hearing evaluation q1–3yr, celiac serology, DXA scan (osteoporosis risk), and renal ultrasound. Fertility: most women with TS are infertile due to ovarian failure; options include egg donation, adoption, or for those with mosaic TS and residual ovarian function, oocyte cryopreservation or fertility preservation. Pregnancy in TS carries high risk of aortic dissection. Follow-up with cardiology and high-risk maternal-fetal medicine is essential.

The 22q11.2 deletion syndrome (the most common microdeletion syndrome, 1 in 2000–4000 live births) is caused by a 1.5–3.0 Mb deletion of chromosome 22q11.2, encompassing approximately 30–50 genes (TBX1 is the most critical). It is a clinical spectrum that includes DiGeorge syndrome, velocardiofacial syndrome (Shprintzen), and conotruncal anomaly face syndrome. Key clinical features: (1) Congenital heart disease (70–80%): conotruncal anomalies are the hallmark — tetralogy of Fallot (most common, 20–30%), interrupted aortic arch type B (characteristic), truncus arteriosus, and ventricular septal defect. (2) Palatal anomalies (50–75%): velopharyngeal incompetence (VPI), submucous cleft palate (bifid uvula, zona pellucida, notched hard palate), or overt cleft palate. (3) Hypocalcemia/hypoparathyroidism (50–70%): presents in the newborn period with hypocalcemic tetany or seizures; treatment: calcium + calcitriol. (4) Thymic aplasia/hypoplasia with T-cell immunodeficiency (80%): low CD3+ T-cell numbers, increased susceptibility to infections, autoimmune disease (ITP, JIA), and risk of severe infection from live vaccines (contraindicated until immunocompetence established). (5) Neuropsychiatric: developmental delay (70–90%), learning disabilities, ADHD (20–40%), anxiety, and a high risk of schizophrenia (25–30% develop psychotic illness by adulthood). (6) Characteristic facies: long narrow face, almond-shaped palpebral fissures, tubular nose with bulbous tip, hypoplastic alae nasi, small mouth, and ear anomalies (overfolded helix, protuberant ears). Other features: feeding difficulties (GERD, dysphagia), renal anomalies (30–40%), hearing loss, skeletal anomalies, and autoimmune conditions. Diagnosis: FISH (fluorescence in situ hybridization) or chromosomal microarray (CMA). Management: multidisciplinary — cardiology for CHD, immunology (T-cell counts, immunoglobulin levels, evaluate for live vaccine eligibility, and treat immunodeficiencies with IVIG and HSCT in severe complete DiGeorge), endocrinology (calcium monitoring, PTH, calcitriol supplementation if needed), plastic surgery/ENT (palatal repair, pharyngoplasty for VPI), genetics, developmental pediatrics, audiology, speech/language therapy, and psychology/psychiatry (including schizophrenia screening in adolescents). Prognosis: variable depending on severity of CHD and immunodeficiency. Advances in cardiac surgery have dramatically improved survival. Individuals with mild phenotypes may live independently; severe cases with complete DiGeorge (absent thymus) require thymus transplant or HSCT.

Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability and the most common monogenic cause of autism spectrum disorder, affecting 1 in 4000–7000 males and 1 in 8000–11,000 females. It is caused by an expansion of the CGG trinucleotide repeat in the 5-untranslated region of the FMR1 gene on the X chromosome. Normal individuals have <45 CGG repeats. Premutation carriers (55–200 repeats) are at risk for fragile X-associated tremor/ataxia syndrome (FXTAS in older males) and fragile X-associated primary ovarian insufficiency (FXPOI in females). Full mutation (>200 CGG repeats) causes hypermethylation and transcriptional silencing of FMR1, leading to absence of FMRP (fragile X mental retardation protein), which is critical for synaptic plasticity and dendritic maturation. Clinical features in males: intellectual disability (moderate to severe), developmental delay — particularly language (speech delays, echolalia, perseverative speech, tangential language), autistic features (poor eye contact, hand flapping, hand biting, social anxiety, sensory overstimulation), hyperactivity, attention deficits (ADHD), and anxiety. Physical features become more prominent with age: long, narrow face, prominent forehead and jaw, large protruding ears, macroorchidism (enlarged testes) after puberty, hyperextensible joints, flat feet, mitral valve prolapse, and pectus excavatum. Females with full mutation have variable expressivity: about 30–50% have intellectual disability (mild-moderate), and the remainder may have learning disabilities, social anxiety, or normal cognition due to X-inactivation skewing favoring the normal X. Diagnosis: FMR1 DNA testing (PCR for CGG repeat number + Southern blot for methylation status). Management: supportive — early intervention programs (PT, OT, speech therapy, behavioral therapy), special education, management of ADHD (stimulants: methylphenidate, behavioral therapy), anxiety (SSRIs: sertraline, fluoxetine), aggressive behaviors (risperidone, aripiprazole, behavioral supports), and sleep disturbances (melatonin). Several targeted pharmacologic therapies (mGluR5 antagonists, GABA-B agonists, minocycline) have been investigated but none is FDA-approved. Family counseling: premutation carrier mothers have up to 50% chance of transmitting the full mutation to each child (expansion risk depends on maternal CGG repeat size: >100 repeats → virtually always expands to full mutation). Prenatal diagnosis (CVS or amniocentesis) and PGD (preimplantation genetic diagnosis) are options. Newborn screening for FXS is not yet universal.

Neurofibromatosis type 1 (NF1, von Recklinghausen disease) is an autosomal dominant disorder with complete penetrance by age 5–8 years, affecting 1 in 3000 individuals. It is caused by mutations in the NF1 gene (17q11.2), which encodes neurofibromin, a tumor suppressor that negatively regulates the Ras-MAPK pathway; loss of function leads to increased Ras signaling and tumorigenesis. Up to 50% of cases are de novo mutations. The diagnostic criteria (NIH Consensus 1987, updated 2021) require 2 or more of the following: (1) Six or more caf-au-lait spots (≥5 mm in prepubertal, ≥15 mm in postpubertal). (2) Axillary or inguinal freckling (Crowe sign, appears 3–5 years after caf-au-lait spots). (3) Two or more Lisch nodules (iris hamartomas, visible on slit-lamp exam, benign, present in >90% of adults with NF1). (4) Optic pathway glioma (15–20%, most common in children <7 years, can cause vision loss, proptosis, precocious puberty if involving the optic chiasm/hypothalamus). (5) Two or more neurofibromas (any type) or one plexiform neurofibroma (benign nerve sheath tumors, can be disfiguring, painful, or transform to malignant peripheral nerve sheath tumors MPNST in 5–10% lifetime risk). (6) Distinctive osseous lesion: sphenoid wing dysplasia (pulsating exophthalmos), long bone bowing/pseudarthrosis (anterior bowing of the tibia leading to fracture and non-union). (7) First-degree relative with NF1. Clinical features evolve with age: caf-au-lait spots appear within the first year, freckling by age 3–5, Lisch nodules by age 10–20, and neurofibromas increase in puberty and pregnancy. Complications: optic glioma (monitor with annual ophthalmology exams; treat with chemotherapy [vincristine + carboplatin] if progressive or vision-threatening), other CNS tumors (brainstem glioma, astrocytoma), cognitive and behavioral difficulties (learning disabilities, ADHD, autism spectrum), scoliosis (10–30%, treat with bracing or surgical correction), hypertension (essential or renovascular from renal artery stenosis or pheochromocytoma), and MPNST (pain, enlargement, or neurologic deficit in a pre-existing plexiform neurofibroma, MRI with PET/CT, surgical resection). Management: multidisciplinary: genetics, neurology, ophthalmology, orthopedics, dermatology, and neurosurgery monitoring for tumor complications. Annual surveillance: ophthalmology (until age 7–8, then q2yr), BP monitoring, scoliosis screening, growth and development, and neurologic exam. No curative therapy exists; MEK inhibitors (selumetinib, trametinib) are FDA-approved for symptomatic, inoperable plexiform neurofibromas (shrinks tumors, reduces pain). Genetic counseling is essential: affected individuals have a 50% chance of passing NF1 to each child. The clinical diagnosis is reliable; molecular testing (NF1 gene sequencing) is available for atypical presentations, prenatal testing, or reproductive planning.

Genetic counseling is the process of helping individuals and families understand and adapt to the medical, psychological, and familial implications of genetic contributions to disease. It includes risk assessment, diagnostic testing options, and counseling about recurrence risk, natural history, management, and psychosocial support. Recurrence risk calculation: (1) Single gene disorders: autosomal dominant (50% for each child if one parent affected, or germline mosaicism in unaffected parents ~1–5%); autosomal recessive (25% for each child if both parents are carriers; carrier frequency 1 in 4–60 depending on population); X-linked recessive (50% of males of a carrier mother affected, 50% of daughters are carriers). (2) Chromosomal: trisomy 21 recurrence risk after a child with nondisjunction is age-dependent (~1% additional risk above maternal age risk); after a translocation carrier, 10–15% if maternal, 2–5% if paternal (lower for balanced carriers). (3) Multifactorial (cleft lip, NTD, CHD): 2–5% recurrence risk for first-degree relatives, dependent on population incidence. Teratogens: Fetal Alcohol Spectrum Disorders (FASD) are caused by maternal alcohol consumption during pregnancy. Fetal alcohol syndrome (FAS) requires all three: characteristic facial features (smooth philtrum, thin vermilion border, small palpebral fissures), prenatal or postnatal growth deficiency (<10th percentile), and CNS abnormalities (microcephaly, intellectual disability, learning disabilities, behavioral problems). No safe amount of alcohol during pregnancy is established; complete abstinence is recommended. Other teratogens: valproate (1–2% NTD risk, reduced IQ, autism, facial dysmorphism; avoid in women of childbearing age if possible), isotretinoin (retinoic acid embryopathy: CNS, cardiac, ear anomalies; must use 2 forms of contraception), warfarin (fetal warfarin syndrome: chondrodysplasia punctata, developmental delay; use LMWH instead), ACE inhibitors (oligohydramnios, renal tubular dysgenesis, skull ossification defects), aminoglycosides (ototoxicity), tetracyclines (dental staining, bone growth inhibition), SSRIs/paroxetine (risk of cardiac septal defects and persistent pulmonary hypertension of the newborn), antiepileptics (carbamazepine, phenytoin: fetal hydantoin syndrome, NTD risk with valproate as above). Newborn screening expansion: the RUSP (Recommended Uniform Screening Panel) now includes 35 core conditions and 26 secondary conditions. Recent additions: spinal muscular atrophy (SMA, SMN1 deletion, wheel base, treatment with nusinersen or onasemnogene), severe combined immunodeficiency (SCID, TREC assay, improves survival with early HSCT from 10% to 94%), Pompe disease (GAA deficiency, enzyme replacement therapy), mucopolysaccharidosis type 1 (Hurler, IDUA deficiency, HSCT), X-linked adrenoleukodystrophy (X-ALD, very long chain fatty acids, treat with Lorenzo oil and HSCT), and critical congenital heart disease (CCHD, pulse oximetry screening). Metabolomics and next-generation sequencing (NGS) are expanding the capabilities of NBS, with the potential for whole-genome sequencing in newborns being actively studied but not yet ready for population-based screening due to ethical, technical, and cost considerations. Future directions: individualized genomic medicine, expanded carrier screening (cystic fibrosis, SMA, fragile X, spinal muscular atrophy, beta-thalassemia, hemoglobinopathies, Tay-Sachs, Canavan, Gaucher, Bloom syndrome, Fanconi anemia in high-risk populations), and pharmacogenomics (e.g., TPMT for 6-MP toxicity, CYP2D6 for codeine metabolism, HLA-B*5701 for abacavir hypersensitivity).